Note: Descriptions are shown in the official language in which they were submitted.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
1
Description
DERIVATIVES OF 2-AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR
PREPARATION AND THEIR USE AS PHARMACEUTICALS
The invention relates to oxadiazolones and to their physiologically acceptable
salts and
physiologically functional derivatives showing PPARdelta agonist activity.
PPARdelta agonists have been described in the prior art (e.g. WO 01/00603, WO
02/092590, W02003/074495, W02004/093879, W02004/080943, W02005/054213
and W02005/097786). Compounds comprising an oxadiazolone feature as inhibitors
of factor Xa were disclosed in DE 101 12 768 Al, oral hypoglycemic agents in
WO
96/13264. From WO 97/40017 compounds having a phenyl group linked to
heterocycles are known as modulators of molecules with phosphotyrosine
recognition
units. Phenyl derivatives as agents for the therapy of thromboembolic
disorders are
known from WO 02/057236. Benzene derivatives as inhibitors of squalene
synthase
and protein farnesyltransferase are described in W096/34851.
The invention was based on the object of providing compounds which permit
therapeutically utilizable modulation of lipid and/or carbohydrate metabolism
and are
thus suitable for the prevention and/or treatment of diseases such as type 2
diabetes
and atherosclerosis and the diverse sequelae thereof. Another purpose of the
invention is to treat demyelinating and other neurodegenerative disorders of
the central
and peripheral nervous systems.
A series of compounds which modulate the activity of PPA receptors has been
found.
The compounds are suitable in particular for activating PPARdelta and
PPARalpha,
however it is possible that the relative activation varies depending on the
specific
compounds.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
2
Compounds of the present invention are described by formula I:
N R5 ~ N ~ R1 H O
u N
-f
N1O
m R2
formula I
wherein
R1 H, halogen, (C1-C8) alkyl, (C0-C4) alkylene-O-(C0-C4) alkylene-H, SCH3,
CN, wherein alkyl and alkylene are unsubstituted or mono, di- or
trisubstituted by F;
R2,,R3,R4 are independently
H, halogen, (C1-C8) alkyl, (C0-C4) alkylene-O-(C0-C4) alkylene-H, SCH3,
CN, wherein alkyl and alkylene are unsubstituted or mono, di- or
trisubstituted by F;
X -CH2-, -CH2-CH2-;
U is S or O;
R5 is H, (C1-C8) alkyl, (Cl-C4) alkylene-O-(C1-C4) alkyl, (Cl-C4) alkylene-O-
(C0-C4) alkylene-(C6-C10) aryl, (C0-C4) alkylene-(C3-C12) cycloalkyl, (C2-
C8) alkenyl, (C0-C4) alkylene-(C3-C15) heterocycloalkyl, (C0-C4) alkylene-
(C3-C15) heterocycloalkenyl, (C0-C4) alkylene-(C5-C15) heteroaryl,
wherein alkyl and alkylene are unsubstituted or mono-, di- or trisubstituted
by F, N((CO-C4) alkylene-H)-(C0-C4) alkylene-H and O-(C0-C4) alkylene-H
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
3
and wherein cycloalkyl, aryl, heterocycloalkyl, heterocycloalkenyl and
heteroaryl are unsubstituted or mono-, di- or trisubstituted by F, Cl, Br,
CF3,
(C1-C4) alkyl, CO-(C1-C4) alkyl and (C0-C4)-alkylen-O-(C0-C4) alkylene-H;
R6, R7 H, (C6-C14) aryl, which is unsubstituted or mono-, di- or
trisubstituted by F,
Cl, Br, CF3, (C1-C4) alkyl and (C0-C4)-alkylen-O-(C0-C4) alkylene-H; or
R6 and R7 together with the oxazole or thiazole ring form a benzothiazole or
benzoxazole ring, which is unsubstituted or mono- di- or trisubstituted by F,
Cl, Br, CF3, (C1-C4) alkyl and (C0-C4)-alkylen-O-(C0-C4) alkylene-H;
in all its stereoisomeric forms, enantiomeric forms and mixtures in any ratio,
and its
physiologically acceptable salts and tautomeric forms.
Another embodiment according to the invention are compounds of the formula I
where
one or more substituents have the following meaning:
R1 halogen, (C1-C8) alkyl, (C0-C4) alkylene-O-(C0-C4) alkylene-H, SCH3, CN,
wherein alkyl and alkylene are unsubstituted or mono, di- or trisubstituted by
F;
R1 is H, F, Cl, (C1-C4) alkyl, O-(C1-C4) alkyl, wherein alkyl and alkylene are
unsubstituted or mono, bi- or trisubstituted by F;
R2,R3,R4 are H;
X is -CH2-CH2-;
X is CH2;
U is S;
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
4
R5 is (C1-C4) alkyl, (C1-C4) alkylene-O-(C1-C4) alkyl, (C1-C4) alkylene-O-
CH2-phenyl, (C1-C4) alkylene-(C5-C6) heterocycloalkyl wherein alkyl and
alkylene can be mono-, di- or trisubstituted by N((C1-C4) alkyl)-(C1-C4) alkyl
and wherein heterocycloalkyl is unsubstituted or monosubstituted by (Cl-
C4) alkyl or CO-(C1-C4) alkyl;
R6 is phenyl monosubstituted by Cl or methoxy;
R6 and R7 together with the thiazole ring denote benzothiazole substituted by
CF3 or
CI.
Another embodiment according to the invention are compounds of the formula I,
wherein
R1 is H, F, CH3 or CF3.
Another embodiment according to the invention are compounds of the formula I,
wherein
R1 is F, CH3 or CF3.
Another embodiment according to the invention are compounds of the formula I,
wherein
R6 and R7 together with the thiazole ring denote 6-trifluoromethyl-
benzothiazole.
Another embodiment according to the invention are the compounds:
3-{4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-phenyl}-4H-[1,2,4]oxadiazol-5-
one
3-{4-[2-(Benzothiazol-2-yl-butyl-amino)-ethyl]-phenyl}-4H-[1,2,4]oxadiazol-5-
one
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
3-(4-{2-[Butyl-(6-methoxy-benzothiazol-2-yl)-amino]-ethyl}-phenyl)-4H-
[1,2,4]oxad iazol-
5-one
5 3-(4-{2-[Butyl-(6-chloro-benzothiazol-2-yl)-amino]-ethyl}-phenyl)-4H-
[1,2,4]oxadiazol-5-
one
3-(4-{2-[Butyl-(6-chloro-benzoth iazol-2-yl)-amino]-ethyl}-2-methyl-phenyl)-4H-
[1,2,4]oxadiazol-5-one
3-(4-{2-[Butyl-(6-trifluoromethyl-benzoth iazol-2-yl)-amino]-ethyl}-2-methyl-
phenyl)-4H-
[1,2,4]oxadiazol-5-one
3-(2-Methyl-4-{2-[[2-(tetrahyd ro-pyran-4-yl)-ethyl]-(6-trifluoromethyl-
benzothiazol-2-yl)-
amino]-ethyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one
3-(2-Methyl-4-{2-[(tetrahyd ro-pyran-3-ylmethyl)-(6-trifluoromethyl-benzoth
iazol-2-yl)-
amino]-ethyl}-phenyl)-4H-[1,2,4]oxad iazol-5-one
3-(2-Methyl-4-{2-[(tetrahydro-pyran-4-ylmethyl)-(6-trifluoromethyl-
benzothiazol-2-yl)-
am ino]-ethyl}-phenyl)-4 H-[ 1, 2,4]oxad iazol-5-one
3-(4-{2-[[2-(1-Acetyl-piperid in-4-yl)-ethyl]-(6-trifluoromethyl-benzothiazol-
2-yl)-amino]-
ethyl}-2-methyl-phenyl)-4H-[1,2,4]oxad iazol-5-one
3-{4-[(Benzooxazol-2-yl-butyl-amino)-methyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one
3-{4-[(Benzothiazol-2-yl-butyl-amino)-methyl]-phenyl}-4H-[1,2,4]oxadiazol-5-
one
3-(4-{[Butyl-(6-chloro-benzothiazol-2-yl)-amino]-methyl}-phenyl)-4H-
[1,2,4]oxadiazol-5-
one
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
6
3-(4-{2-[(3-Methoxy-p ropyl)-(6-trifluoromethyl-benzoth iazol-2-yl)-am i no]-
ethyl}-2-
methyl-phenyl)-4H-[1,2,4]oxad iazol-5-one
3-(4-{2-[[2-(2-Methoxy-ethoxy)-ethyl]-(6-trifluoromethyl-benzothiazol-2-yl)-am
ino]-
ethyl}-2-methyl-phenyl)-4H-[1,2,4]oxad iazol-5-one
3-(4-{2-[(2-Benzyloxy-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
ethyl}-2-
methyl-phenyl)-4H-[1,2,4]oxadiazol-5-one
3-(4-{2-[(2-Methoxy-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-ethyl}-
2-methyl-
phenyl)-4H-[1,2,4]oxadiazol-5-one
3-[4-(2-{Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-amino}-ethyl)-phenyl]-4H-
[1,2,4]oxadiazol-5-one
3-[4-(2-{Butyl-[4-(4-chloro-phenyl)-thiazol-2-yl]-amino}-ethyl)-phenyl]-4H-
[1,2,4]oxadiazol-5-one
3-(4-{2-[[4-(4-Chloro-phenyl)-thiazol-2-yl]-(3-methoxy-propyl)-am ino]-ethyl}-
phenyl)-4H-
[1,2,4]oxadiazol-5-one
3-[4-(2-{[4-(4-Chloro-phenyl)-thiazol-2-yl]-[2-(2-methoxy-ethoxy)-ethyl]-
amino}-ethyl)-
phenyl]-4H-[1,2,4]oxadiazol-5-one
3-[4-(2-{(2-Benzyloxy-ethyl)-[4-(4-chloro-phenyl)-thiazol-2-yl]-amino}-ethyl)-
phenyl]-4H-
[1,2,4]oxadiazol-5-one
3-(4-{2-[[4-(4-Chloro-phenyl)-thiazol-2-yl]-(2-methoxy-ethyl)-amino]-ethyl}-
phenyl)-4H-
[1,2,4]oxadiazol-5-one
3-(4-{[Butyl-(6-trifluoromethyl-benzothiazol-2-yl)-am ino]-methyl}-2-fluoro-
phenyl)-4H-
[1,2,4]oxadiazol-5-one
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
7
3-(4-{[Butyl-(6-chloro-benzothiazol-2-yl)-amino]-methyl}-2-fluoro-phenyl)-4H-
[1,2,4]oxadiazol-5-one
3-(2-Fluoro-4-{[(2-pyrrolidin-1-yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-
yl)-amino]-
methyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
3-(4-{[(2-Dimethylam ino-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-am ino]-
methyl}-2-
fluoro-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
3-(2-Fluoro-4-{[(2-methoxy-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
methyl}-
phenyl)-4H-[1,2,4]oxadiazol-5-one
3-(2-Fluoro-4-{[(2-piperidin-1 -yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-
yl)-amino]-
methyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
3-(2-Fluoro-4-{[(2-morphol in-4-yl-ethyl)-(6-trifluoromethyl-benzoth iazol-2-
yl)-amino]-
methyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
3-(2-Fluoro-4-{[[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-(6-trifluoromethyl-
benzothiazol-2-yl)-
amino]-methyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
3-(4-{[(2-Pyrrol id in-1-yl-ethyl)-(6-trifl uoromethyl-benzoth iazol-2-yl)-am
ino]-methyl}-2-
trifluoromethyl-phenyl)-4H-[1,2,4]oxad iazol-5-one
3-(4-{[(2-Dimethylamino-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
methyl}-2-
trifluoromethyl-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
3-(4-{[(2-Methoxy-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-
2-
trifluoromethyl-phenyl)-4H-[1,2,4]oxad iazol-5-one
3-(4-{[(2-Piperidin-1-yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
methyl}-2-
trifluoromethyl-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
8
3-(4-{[(2-Morpholin-4-yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
methyl}-2-
trifluoromethyl-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
3-(4-{[[2-(1-Methyl-pyrrolidin-2-yl)-ethyl]-(6-trifluoromethyl-benzothiazol-2-
yl)-amino]-
methyl}-2-trifluoromethyl-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
3-[4-({Butyl-[4-(4-methoxy-phenyl)-th iazol-2-yl]-amino}-methyl)-phenyl]-4H-
[1,2,4]oxadiazol-5-one
3-(4-{[[4-(4-Chloro-phenyl)-thiazol-2-yl]-(3-methoxy-propyl)-amino]-methyl}-2-
fluoro-
phenyl)-4H-[1,2,4]oxadiazol-5-one
3-(4-{[[4-(4-Chloro-phenyl)-thiazol-2-yl]-(2-methoxy-ethyl)-amino]-methyl}-2-
fluoro-
phenyl)-4H-[1,2,4]oxadiazol-5-one
3-[4-({[4-(4-Ch loro-phenyl)-thiazol-2-yl]-[2-(2-methoxy-ethoxy)-ethyl]-amino}-
methyl)-2-
fluoro-phenyl]-4H-[1,2,4]oxadiazol-5-one
This invention also encompasses all combinations of preferred aspects of the
invention
described herein.
As used herein, the term alkyl is to be understood in the broadest sense to
mean
saturated hydrocarbon residues which can be linear, i. e. straight-chain, or
branched. If
not otherwise defined alkyl has 1 to 8 carbon atoms. Examples of "-(C1-C8)-
a1kyI" are
alkyl residues containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms are methyl,
ethyl, propyl,
butyl, pentyl, hexyl, heptyl or octyl, the n-isomers of all these residues,
isopropyl,
isobutyl, 1-methylbutyl, isopentyl, neopentyl, 2,2-dimethylbutyl, 2-
methylpentyl, 3-
methylpentyl, isohexyl, sec-butyl, tert-butyl or tert-pentyl. The term "-(C0-
C8)-alkyl" is a
hydrocarbon residue containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, in which
the term
"-CO-alkyl" is a covalent bond. All these statements apply also to the term
alkylene.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
9
As used herein, the term alkenyl is to be understood in the broadest sense to
mean
hydrocarbon residues which has 1 to 4 double bonds and can be linear, i. e.
straight-
chain, or branched. If not otherwise defined alkenyl has 2 to 8 carbon atoms.
Examples of "-(C2-C8)-alkenyl" are alkenyl residues containing 2, 3, 4, 5, 6,
7 or 8
carbon atoms are, for example vinyl, 1-propenyl, 2-propenyl (= allyl), 2-
butenyl, 3-
butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 5-hexenyl or 1,3-pentadienyl.
All these
statements apply also to the term alkenylene.
As used herein, the term alkinyl is to be understood in the broadest sense to
mean
hydrocarbon residues, which has 1 to 4 triple bonds and can be linear, i. e.
straight-
chain, or branched. If not otherwise defined alkinyl has 2 to 8 carbon atoms.
Examples
of "-(C2-C8)-alkinyl" are alkinyl residues containing 2, 3, 4, 5, 6, 7 or 8
carbon atoms
are, for example ethynyl, 1-propynyl, 2-propynyl (= propargyl) or 2-butynyl.
All these
statements apply also to the term alkylidene.
All these statements also apply if an alkyl group occurs as a substituent on
another
residue, for example in an alkyloxy residue, an alkyloxycarbonyl residue or an
arylalkyl
residue.
If not otherwise defined, alkyl, alkylene, alkenyl, alkenylene, alkinyl and
alkinylene are
unsubstituted or mono, di- or trisubstituted independently of one another by
suitable
groups such as, for example: F, CI, Br, I, CF3, N02, CN, COOH, CO-O-(CO-C4)
alkylene-(C6-C10) aryl, CO-O-(C1-C4) alkyl, CO-O-(CO-C4) alkylene-(C3-
C13)cycloalkyl, CO-O-(CO-C4) alkylene-(C3-C15)heterocycle, CO-N((CO-C4)
alkylene-
H)-(CO-C4) alkylene- (C6-C10) aryl, CO-N((CO-C4) alkylene-H)-(C0-C4) alkylene-
H,
CO-N((CO-C4) alkylene-H)-(C0-C4) alkylene- (C3-C13)cycloalkyl, CO-N((CO-C4)
alkylene-H)-(C0-C4) alkylene- (C3-C15) heterocycle, (C0-C4) alkylene-(C3-
C6)cycloalkyl, (C0-C4) alkylene-(C6-C10)aryl, (C0-C4) alkylene-(C3-
C15)heterocycle,
(C2-C6)-alkenyl, (C2-C6)-alkinyl, O-(C0-C6)-alkyl, O-(C0-C4) alkylene-(C6-C10)
aryl,
O-(C0-C4) alkylene-(C3-C12)cycloalkyl, O-(C0-C4) alkylene-(C3-C 15)
heterocycle, 0-
CO-O-(C0-C4) alkylene-(C6-C10) aryl, O-CO-O-(C1-C4) alkyl, O-CO-O-(C0-C4)
alkylene-(C3-C13)cycloalkyl, O-CO-O-(C0-C4) alkylene-(C3-C15)heterocycle, S-
(C1-
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
C4)alkyl, S-(C0-C4) alkylene-(C3-C13)cycloalkyl, S-(C0-C4) alkylene-(C6-C10)
aryl, S-
(C0-C4) alkylene-(C3-C15) heterocycle, SO-(C1-C4)alkyl, SO-(CO-C4) alkylene-
(C3-
C13)cycloalkyl, SO-(CO-C4) alkylene-(C6-C10) aryl, SO-(CO-C4) alkylene-(C3-
C15)
heterocycle, S02-(C1-C4)alkyl, S02-(C0-C4) alkylene-(C3-C13)cycloalkyl, S02-
(C0-
5 C4) alkylene-(C6-C10) aryl, S02-(C0-C4) alkylene-(C3-C15) heterocycle, S02-
N((C0-
C4)alkylene-H)-(C0-C4)alkylene-(C6-C 10)aryl, S02-N((C0-C4)alkylene-H)-(C0-
C4)alkylene-H, S02-N((C0-C4) alkylene-H)-(CO-C4)alkylene-(C3-C13)cycloalkyl,
S02-
N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C3-C15)heterocyclewhere the aryl ring or
heterocyclic ring is unsubstituted or mono- or disubstituted by F, Cl, Br, OH,
CF3, N02,
10 CN, OCF3, O-(C1-C6)-alkyl, (C1-C6)-alkyl, N((C0-C4)-alkylene-H)-(C0-C4)-
alkylene-H;
N((C0-C4)-alkylene-H)-(C0-C4)-alkylene-H, N((CO-C4) alkylene-H)-(C0-
C4)alkylene-
H)-(C1-C6)cycloalkyl, N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C6-C12)-aryl,
N((C0-
C4)alkylene-H)-(C0-C4)alkylene-(C3-C15)heterocycle, N((CO-C4) alkylene-H)-CO-
(C0-C4)alkylene-(C6-C12)-aryl, N((C0-C4)alkylene-H)-CO-(C0-C4)alkyl, N((CO-
C4)alkylene-H)-CO-(C0-C4)alkylene-(C3-C 13)cycloalkyl, N((C0-C4)alkylene-H)-CO-
(C0-C4)alkylene-(C3-C15)heterocycle, N((CO-C4) alkylene-H)-CO-O-(C0-
C4)alkylene-(C6-C12)-aryl, N((C0-C4)alkylene-H)-CO-O-(C0-C4)alkyl, N((C0-
C4)alkylene-H)-CO-O-(C0-C4)alkylene-(C3-C13)cycloalkyl, N((C0-C4)alkylene-H)-
CO-O-(C0-C4)alkylene-(C3-C15)heterocycle, N((CO-C4) alkylene-H)-CO-N((C0-C4)-
alkylene-H)-(C0-C4)alkylene-(C6-C12)-aryl, N((C0-C4)alkylene-H)-CO-N((C0-C4)-
alkylene-H)-(C0-C4)alkyl, N((C0-C4)alkylene-H)-CO-N((C0-C4)-alkylene-H)-(C0-
C4)alkylene-(C3-C13)cycloalkyl, N((C0-C4)alkylene-H)-CO-N((C0-C4)-alkylene-H)-
(C0-C4)alkylene-(C3-C15)heterocycle, where the aryl ring or heterocyclic ring
is
unsubstituted or mono- or disubstituted by F, Cl, Br, I, OH, CF3, N02, CN,
OCF3, 0-
(C1-C6)-alkyl, (C1-C6)-alkyl, N((CO-C4)-alkylene-H)-(C0-C4)-alkylene-H, SO2-
CH3,
COOH, COO-(C1-C6)-alkyl, SF5, CONH2.
The term cycloalkyl is to be understood to mean saturated hydrocarbon cycle
containing from 3 to 13 carbon atoms in a mono- or bicyclic, fused, bridged or
spirocyclic ring. Examples of (C3-C13)-cycloalkyl cyclic alkyl residues are
cycloalkyl
residues containing 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 ring carbon atoms
like
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
cyclononyl,
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
11
cyclodecyl, cycloundecyl or cyclododecyl. The term cycloalkyl also includes
bicyclic
groups in which any of the above cycloalkyl ring is fused to a benzene ring,
for
example indane and 1,2,3,4-tetrahydronaphthalene.
The term cycloalkenyl is to be understood to mean unsaturated hydrocarbon
cycle
containing from 3 to 8 carbon atoms in a mono- or bicyclic, fused or bridged
ring,
wherein the one, two or three double bonds are not located within a cyclic
alkyl group
in such a manner that an aromatic system results. Examples of unsaturated
cycloalkenyl groups are cyclopentenyl or cyclohexenyl, which can be bonded via
any
carbon atom. The term cycloalkenyl also includes bicyclic groups in which any
of the
above cycloalkenyl ring is fused to a benzene ring, for example 1,2-
dihydronaphthalene, 1,4-dihydronaphthalene and 1H-indene.
If not otherwise defined cycloalkyl or cycloalkenyl are unsubstituted or mono,
di- or
trisubstituted independently of one another by suitable groups such as, for
example: F,
Cl, Br, I, CF3, N02, CN, COOH, CO-O-(CO-C4) alkylene-(C6-C10) aryl, CO-O-(C1-
C4)
alkyl, CO-O-(CO-C4) alkylene-(C3-C13)cycloalkyl, CO-O-(CO-C4) alkylene-(C3-
C15)heterocycleõ CO-N((CO-C4) alkylene-H)-(C1-C6)alkylene-H, CO-N((CO-C4)
alkylene-H)-(C 1-C6)cycloalkyl, CON((CO-C4) alkylene-H)-(C0-C4)alkylene-(C6-C
12)-
aryl, (C0-C4) alkylene-(C3-C6)cycloalkyl, (C3-C6)alkyl, (C2-C6)-alkenyl, (C2-
C6)-
alkinyl, (C0-C4) alkylene-(C6-C10)aryl, (C0-C4) alkylene-(C3-C15)heterocycle,
O-(C0-
C6)-alkyl, (C0-C4) alkylene-O-(C0-C4) alkyl, (C0-C4) alkylene-O-(C0-C4)
alkylene-
(C3-C13)cycloalkyl, (C0-C4) alkylene-O-(C0-C4) alkylene-(C6-C10)aryl, (C0-C4)
alkylene-O-(C0-C4) alkylene-(C3-C15)heterocycle, O-CO-O-(C0-C4) alkylene-(C6-
C10) aryl, O-CO-O-(C1-C4) alkyl, O-CO-O-(C0-C4) alkylene-(C3-C13)cycloalkyl, 0-
CO-O-(C0-C4) alkylene-(C3-C 1 5)heterocycle, O-CO-N((C0-C4) alkylene-H)-(C0-
C4)
alkylene- (C6-C10) aryl, O-CO-N((C0-C4) alkylene-H)-(C0-C4) alkylene-H, O-CO-
N((C0-C4) alkylene-H)-(C0-C4) alkylene- (C3-C13)cycloalkyl, O-CO-N((C0-C4)
alkylene-H)-(C0-C4) alkylene- (C3-C15) heterocycle, S-(C 1 -C4)alkyl, S-(C0-
C4)
alkylene-(C3-C13)cycloalkyl, S-(C0-C4) alkylene-(C6-C10) aryl, S-(C0-C4)
alkylene-
(C3-C15) heterocycle, SO-(C1-C4)alkyl, SO-(CO-C4) alkylene-(C3-C13)cycloalkyl,
SO-
(C0-C4) alkylene-(C6-C10) aryl, SO-(CO-C4) alkylene-(C3-C15) heterocycle, S02-
(C1-
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
12
C4)alkyl, S02-(C0-C4) alkylene-(C3-C13)cycloalkyl, S02-(C0-C4) alkylene-(C6-
C10)
aryl, S02-(C0-C4) alkylene-(C3-C15) heterocycle, S02-N((C0-C4)alkylene-H)-(C0-
C4)alkylene-(C6-C10)aryl, S02-N((C0-C4)alkylene-H)-(C0-C4)alkylene-H, S02-
N((CO-
C4) alkylene-H)-(C0-C4)alkylene-(C3-C 13)cycloalkyl, S02-N((C0-C4)alkylene-H)-
(C0-
C4)alkylene-(C3-C15)heterocycle, where the aryl ring or heterocyclic ring is
unsubstituted or mono- or disubstituted by F, Cl, Br, OH, CF3, N02, CN, OCF3,
O-
(C 1-C6)-alkyl, (C 1-C6)-alkyl, N((C0-C4)-alkylene-H)-(C0-C4)-alkylene-H;
N((C0-C4)-alkylene-H)-(C0-C4)-alkylene-H, N((CO-C4) alkylene-H)-(C0-
C4)alkylene-
H)-(C1-C6)cycloalkyl, N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C6-C12)-aryl,
N((C0-
C4)alkylene-H)-(C0-C4)alkylene-(C3-C15)heterocycle, N((CO-C4) alkylene-H)-CO-
(C0-C4)alkylene-(C6-C12)-aryl, N((C0-C4)alkylene-H)-CO-(C0-C4)alkyl, N((CO-
C4)alkylene-H)-CO-(C0-C4)alkylene-(C3-C 13)cycloalkyl, N((C0-C4)alkylene-H)-CO-
(C0-C4)alkylene-(C3-C 15)heterocycle, N ((CO-C4) alkylene-H)-CO-O-(C0-
C4)alkylene-(C6-C12)-aryl, N((C0-C4)alkylene-H)-CO-O-(C0-C4)alkyl, N((C0-
C4)alkylene-H)-CO-O-(C0-C4)alkylene-(C3-C13)cycloalkyl, N((C0-C4)alkylene-H)-
CO-O-(C0-C4)alkylene-(C3-C15)heterocycle, N((CO-C4) alkylene-H)-CO-N((C0-C4)-
alkylene-H)-(C0-C4)alkylene-(C6-C12)-aryl, N((C0-C4)alkylene-H)-CO-N((C0-C4)-
alkylene-H)-(C0-C4)alkyl, N((C0-C4)alkylene-H)-CO-N((C0-C4)-alkylene-H)-(C0-
C4)alkylene-(C3-C13)cycloalkyl, N((C0-C4)alkylene-H)-CO-N((C0-C4)-alkylene-H)-
(C0-C4)alkylene-(C3-C15)heterocycle, where the aryl or heterocyclic ring is
unsubstituted or mono- or disubstituted by F, Cl, Br, I, OH, CF3, N02, CN,
OCF3, 0-
(C1-C6)-alkyl, (C1-C6)-alkyl, N((C0-C4)-alkylene-H)-(C0-C4)-alkylene-H,SO2-
CH3,
COOH, COO-(C1-C6)-alkyl, SF5, CONH2.
The term "aryl" is understood to mean aromatic hydrocarbon ring containing
from 6 to
14 carbon atoms in a mono- or bicyclic ring. Examples of (C6-C14)-aryl rings
are
phenyl, naphthyl, for example 1-naphthyl and 2-naphthyl, biphenylyl, for
example 2-
biphenylyl, 3-biphenylyl and 4-biphenylyl, anthryl or fluorenyl. Biphenylyl
rings,
naphthyl ringand, in particular, phenyl ringare further embodiments of aryl
ring.
The terms heterocycle is understood to mean saturated (heterocycloalkyl),
partly
unsaturated (heterocycloalkenyl) or unsaturated (heteroaryl) hydrocarbon rings
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
13
containing from 3 to 15 carbon atoms in a mono- or bicyclic , fused, bridged
or
spirocyclicring in which 1 to 5 carbon atoms of the 3 to 15 ring carbon atoms
are
replaced by heteroatoms such as nitrogen, oxygen or sulfur in which further
the
heteroatoms can be oxidized, for example N=O, S=O, S02. Examples of
heterocycles
are acridinyl, azaindole (1 H-pyrrolopyridinyl), azabenzimidazolyl,
azaspirodecanyl,
azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl,
dihydrobenzofuranyl,
benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl,
benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl,
carbolinyl,
chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxazolinyl,
dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 3,3-
dioxo[1,3,4]oxathiazinyl, 6H-
1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl,
imidazolidinyl,
imidazolinyl, imidazolyl, 1 H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-
indolyl,
isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl,
isoquinolinyl
(benzimidazolyl), isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl,
isoxazolinyl,
isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl,
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl,
1,2,5-
oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-
oxazepanyl, 1,4-
oxazepinyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl,
oxazolinyl, oxazolyl,
oxetanyl, oxocanyl, phenanthridinyl, phenanthrolinyl, phenazinyl,
phenothiazinyl,
phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl,
pteridinyl, purinyl,
pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl,
pyridooxazolyl,
pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl,
pyrrolidinyl,
pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl,
4H-quinolizinyl,
quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl,
tetrahydroquinolinyl, tetra hyd rofu ranyl, tetrahydropyranyl,
tetrahydropyridinyl,
tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-
thiadiazolyl,
1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-
thiazinyl, 1,3-
thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl,
thiazolinyl, thienyl, thietanyl,
thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl,
thiophenolyl,
thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,
1,2,3-triazolyl,
1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and
xanthenyl.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
14
The heterocyclic rings are unsubstituted or mono-, di- or trisubstituted by
suitable
groups such as, for example: F, CI, Br, I, CF3, N02, CN, COOH, CO-O-(CO-C4)
alkylene-(C6-C10) aryl, CO-O-(C1-C4) alkyl, CO-O-(CO-C4) alkylene-(C3-
C13)cycloalkyl, CO-O-(CO-C4) alkylene-(C3-C15)heterocycleõ CO-N((CO-C4)
alkylene-H)-(C1-C6)alkylene-H, CO-N((CO-C4) alkylene-H)-(C1-C6)cycloalkyl,
CON((CO-C4) alkylene-H)-(C0-C4)alkylene-(C6-C12)-aryl, (C0-C4) alkylene-(C3-
C6)cycloalkyl, (C3-C6)alkyl, (C2-C6)-alkenyl, (C2-C6)-alkinyl, (C0-C4)
alkylene-(C6-
C10)aryl, (C0-C4) alkylene-(C3-C15)heterocycle, O-(C0-C6)-alkyl, (C0-C4)
alkylene-O-
(C0-C4) alkyl, (C0-C4) alkylene-O-(C0-C4) alkylene-(C3-C13)cycloalkyl, (C0-C4)
alkylene-O-(C0-C4) alkylene-(C6-C10)aryl, (C0-C4) alkylene-O-(C0-C4) alkylene-
(C3-
C 15) heterocycle, O-CO-O-(C0-C4) alkylene-(C6-C10) aryl, O-CO-O-(C1-C4)
alkyl, 0-
CO-O-(C0-C4) alkylene-(C3-C13)cycloalkyl, O-CO-O-(C0-C4) alkylene-(C3-
C15)heterocycle, O-CO-N((C0-C4) alkylene-H)-(C0-C4) alkylene- (C6-C10) aryl, 0-
CO-N((C0-C4) alkylene-H)-(C0-C4) alkylene-H, O-CO-N((C0-C4) alkylene-H)-(C0-
C4)
alkylene- (C3-C13)cycloalkyl, O-CO-N((C0-C4) alkylene-H)-(C0-C4) alkylene- (C3-
C15) heterocycle, S-(C 1 -C4)alkyl, S-(C0-C4) alkylene-(C3-C13)cycloalkyl, S-
(C0-C4)
alkylene-(C6-C10) aryl, S-(C0-C4) alkylene-(C3-C15) heterocycle, SO-(C1-
C4)alkyl,
SO-(CO-C4) alkylene-(C3-C13)cycloalkyl, SO-(CO-C4) alkylene-(C6-C10) aryl, SO-
(CO-
C4) alkylene-(C3-C15) heterocycle, S02-(C1-C4)alkyl, S02-(C0-C4) alkylene-(C3-
C13)cycloalkyl, S02-(C0-C4) alkylene-(C6-C10) aryl, S02-(C0-C4) alkylene-(C3-
C15)
heterocycle, S02-N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C6-C 10)aryl, S02-N((C0-
C4)alkylene-H)-(C0-C4)alkylene-H, S02-N((C0-C4) alkylene-H)-(C0-C4)alkylene-
(C3-
C 13)cycloalkyl, S02-N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C3-C
15)heterocycle,
where the aryl ring or heterocyclic ring is unsubstituted or mono- or
disubstituted by F,
Cl, Br, OH, CF3, N02, CN, OCF3, 0-(C1-C6)-alkyl, (C1-C6)-alkyl, N((C0-C4)-
alkylene-
H)-(C0-C4)-alkylene-H,;
N((C0-C4)-alkylene-H)-(C0-C4)-alkylene-H, N((CO-C4) alkylene-H)-(C0-
C4)alkylene-
H)-(C1-C6)cycloalkyl, N((C0-C4)alkylene-H)-(C0-C4)alkylene-(C6-C12)-aryl,
N((CO-
C4)alkylene-H)-(C0-C4)alkylene-(C3-C15)heterocycle, N((CO-C4) alkylene-H)-CO-
(C0-
C4)alkylene-(C6-C12)-aryl, N((C0-C4)alkylene-H)-CO-(C0-C4)alkyl, N((C0-
C4)alkylene-H)-CO-(C0-C4)alkylene-(C3-C 13)cycloalkyl, N((C0-C4)alkylene-H)-CO-
(C0-C4)alkylene-(C3-C 15) heterocycle, N((CO-C4) alkylene-H)-CO-O-(C0-
C4)alkylene-
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
(C6-C12)-aryl, N((C0-C4)alkylene-H)-CO-O-(C0-C4)alkyl, N((C0-C4)alkylene-H)-CO-
O-(C0-C4)alkylene-(C3-C13)cycloalkyl, N((C0-C4)alkylene-H)-CO-O-(C0-
C4)alkylene-
(C3-C15)heterocycle, N((CO-C4) alkylene-H)-CO-N((C0-C4)-alkylene-H)-(C0-
C4)alkylene-(C6-C12)-aryl, N((C0-C4)alkylene-H)-CO-N((C0-C4)-alkylene-H)-(C0-
5 C4)alkyl, N((C0-C4)alkylene-H)-CO-N((C0-C4)-alkylene-H)-(C0-C4)alkylene-(C3-
C13)cycloalkyl, N((C0-C4)alkylene-H)-CO-N((C0-C4)-alkylene-H)-(C0-C4)alkylene-
(C3-C15)heterocycle, where the aryl or heterocyclic ring is unsubstituted or
mono- or
disubstituted by F, Cl, Br, I, OH, CF3, N02, CN, OCF3, O-(C1-C6)-alkyl, (C1-
C6)-alkyl,
N((C0-C4)-alkylene-H)-(C0-C4)-alkylene-H,S02-CH3, COOH, COO-(C1-C6)-alkyl,
10 SF5, CONH2.
The term "oxo-residue" or "=0" refers to residues such as carbonyl (-CO-),
nitroso (-
N=O), sulfinyl (-SO- or sulfonyl (-SO2-).
15 Halogen is fluorine, chlorine, bromine or iodine.
Optically active carbon atoms present in the compounds of the formula I can
independently of each other have R configuration or S configuration. The
compounds
of the formula I can be present in the form of pure enantiomers or pure
diastereomers
or in the form of mixtures of enantiomers and/or diastereomers, for example in
the form
of racemates. The present invention relates to pure enantiomers and mixtures
of
enantiomers as well as to pure diastereomers and mixtures of diastereomers.
The
invention comprises mixtures of two or of more than two stereoisomers of the
formula I
and it comprises all ratios of the stereoisomers in the mixtures. In case the
compounds
of the formula I can be present as E isomers or Z isomers (or cis isomers or
trans
isomers) the invention relates both to pure E isomers and pure Z isomers and
to E/Z
mixtures in all ratios. The invention also comprises all tautomeric forms of
the
compounds of the formula I.
Diastereomers, including E/Z isomers, can be separated into the individual
isomers, for
example, by chromatography. Racemates can be separated into the two
enantiomers
by customary methods, for example by chromatography on chiral phases or by
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
16
resolution, for example by crystallization of diastereomeric salts obtained
with optically
active acids or bases. Stereochemically uniform compounds of the formula I can
also
be obtained by employing stereochemically uniform starting materials or by
using
stereoselective reactions.
The compounds of the formula I may exist in the form of their racemates,
racemic
mixtures, pure enantiomers, diastereomers and mixtures of diastereomers as
well in
their tautomeric forms. The present invention encompasses all these isomeric
and
tautomeric forms of the compounds of the formula I. These isomeric forms can
be
obtained by known methods even if not specifically described in some cases.
Pharmaceutically acceptable salts are, because their solubility in water is
greater than
that of the initial or basic compounds, particularly suitable for medical
applications.
These salts must have a pharmaceutically acceptable anion or cation. Suitable
pharmaceutically acceptable acid addition salts of the compounds of the
invention are
salts of inorganic acids such as hydrochloric acid, hydrobromic, phosphoric,
metaphosphoric, nitric and sulfuric acid, and of organic acids such as, for
example,
acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric,
gluconic, glycolic,
isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic,
p-toluenesulfonic and tartaric acid. Suitable pharmaceutically acceptable
basic salts
are ammonium salts, alkali metal salts (such as sodium and potassium salts),
alkaline
earth metal salts (such as magnesium and calcium salts), and salts of
trometamol
(2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine or
ethylenediamine.
Salts with a pharmaceutically unacceptable anion such as, for example,
trifluoroacetate likewise belong within the framework of the invention as
useful
intermediates for the preparation or purification of pharmaceutically
acceptable salts
and/or for use in nontherapeutic, for example in vitro, applications.
The term "physiologically functional derivative" used herein refers to any
physiologically tolerated derivative of a compound of the formula I of the
invention, for
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
17
example an ester, which on administration to a mammal such as, for example, a
human is able to form (directly or indirectly) a compound of the formula I or
an active
metabolite thereof.
Physiologically functional derivatives also include prodrugs of the compounds
of the
invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull.
1994, 42,
57-61. Such prodrugs can be metabolized in vivo to a compound of the
invention.
These prodrugs may themselves be active or not.
The compounds of the invention may also exist in various polymorphous forms,
for
example as amorphous and crystalline polymorphous forms. All polymorphous
forms
of the compounds of the invention belong within the framework of the invention
and are
a further aspect of the invention.
All references to "compound(s) of formula I" hereinafter refer to compound(s)
of the
formula I as described above, and their salts, solvates and physiologically
functional
derivatives as described herein.
Use
This invention relates further to the use of compounds of the formula I and
their
pharmaceutical compositions as PPAR ligands. The PPAR ligands of the invention
are
suitable as modulators of PPAR activity.
Peroxisome proliferator-activated receptors (PPAR) are transcription factors
which can
be activated by ligands and belong to the class of nuclear hormone receptors.
There
are three PPAR isoforms, PPARalpha, PPARgamma and PPARdelta (identical to
PPARbeta), which are encoded by different genes (Peroxisome proliferator-
activated
receptor (PPAR): structure, mechanisms of activation and diverse functions:
Motojima
K., Cell Struct Funct., 1993, 18(5), 267-77).
In humans, PPARgamma exists in three variants, PPARgammal, gamma2, and
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
18
gamma3, which are the result of alternative use of promoters and differential
mRNA
splicing. Different PPARs have different tissue distribution and modulate
different
physiological functions. The PPARs play a key role in various aspects of the
regulation
of a large number of genes, the products of which genes are directly or
indirectly
crucially involved in lipid and carbohydrate metabolism. Thus, for example,
the
PPARalpha receptor plays an important part in the regulation of fatty acid
catabolism
or lipoprotein metabolism in the liver, while PPARgamma is crucially involved
for
example in regulating adipose cell differentiation. In addition, however,
PPARs are also
involved in the regulation of many other physiological processes, including
those which
are not directly connected with carbohydrate or lipid metabolism. The activity
of
different PPARs can be modulated by various fatty acids, fatty acid
derivatives and
synthetic compounds to varying extents. For relevant reviews about functions,
physiological effects and pathophysiology, see: Berger, J. et al., Annu. Rev.
Med.,
2002, 53, 409-435; Wilson, T. et al., J. Med. Chem., 2000, 43 (4), 527-550;
Kliewer, S.
et al., Recent Prog Horm Res., 2001, 56, 239-63; Moller, D.E. and Berger,
J.P., Int J
Obes Relat Metab Disord., 2003, 27 Suppl 3, 17-21; Ram, V.J., Drugs Today,
2003,
39(8),609-32).
Among the three PPAR-isoforms the physiological functions of PPARdelta have
long
remained an enigma. The first proposed pharmacological role for PPARdelta has
been
the regulation of cholesterol homeostasis. It was shown that the somewhat
selective
PPARdelta ligand L-165041 raises plasma cholesterol in a diabetic animal model
(Berger J. et al., J. Biol. Chem., 1999, 274, 6718-6725; Leibowitz M.D. et
al., FEBS
Left., 2000, 473(3), 333-336). In obese, insulin resistant rhesus monkeys, the
potent
and selective PPARdelta ligand GW501516 raises HDL-cholesterol, decreases
plasma
LDL-cholesterol, triglycerides and insulin levels (Oliver, W. et al., Proc.
Natl. Acad.
Sci., 2001, 98, 5306-5311). The dual PPARdelta/PPARalpha agonist YM-16638
significantly lowers plasma lipids in rhesus and cynomolgus monkeys (Goto, S.
et al.,
Br. J. Pharm., 1996, 118, 174-178) and acts in a similar manner in two weeks
clinical
trials in healthy volunteers (Shimokawa, T. et al., Drug Dev. Res., 1996, 38,
86-92).
More recent publications underline that PPARdelta is an important target for
the
treatment of dyslipidemia, insulin resistance, type 2 diabetes,
atherosclerosis and
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
19
syndrom X (Wang,Y-X. et al., Cell, 2003, 113, 159-170; Luquet, S. et al.,
FASEB J.,
2003, 17, 209-226 ; Tanaka, T. et al., PNAS, 2003, 100, 15924-15929 ; Holst,
D. et al.,
BioChem. Biophys. Acta, 2003, 1633, 43-50; Dressel, U. et al., Mol. Endocrin.,
2003,
17, 2477-2493 ; Lee, C.H. et al., Science, 2003, 302, 453-457).
Besides its actions as a regulator of the lipid-, glucose- and cholesterol-
metabolism
PPARdelta is known to play a role in embryonic development, implantation and
bone
formation (Lim, H. and Dey, S.K., Trends Endocrinol Metab., 2000, 11(4),137-
42; Ding,
N.Z. et al., Mol Reprod Dev., 2003, 66(3), 218-24; Mano, H. et al., J Biol
Chem., 2000,
275(11), 8126-32).
Numerous publications demonstrate that PPARdelta is triggering proliferation
and
differentiation of keratinocytes which points to its role in skin disorders
and wound
healing (Di-Poi, N. et al., J Steroid Biochem Mol Biol., 2003, 85(2-5), 257-
65; Tan, N.S.
et al., Am J Clin Dermatol., 2003,4(8), 523-30; Wahli, W., Swiss Med Wkly.,
2002,
132(7-8),83-91).
PPARdelta appears to be significantly expressed in the CNS; however much of
its
function there still remains undiscovered. Of singular interest however, is
the
discovery that PPARdelta was expressed in rodent oligodendrocytes, the major
lipid
producing cells of the CNS (J. Granneman, et al., J. Neurosci. Res., 1998, 51,
563-
573). Moreover, it was also found that a PPARdelta selective agonist was found
to
significantly increase oligodendroglial myelin gene expression and myelin
sheath
diameter in mouse cultures (I. Saluja et al., Glia, 2001, 33, 194-204). Thus,
PPARdelta activators may be of use for the treatment of demyelinating and
dysmyelinating diseases. The use of peroxisome proliferator activated receptor
delta
agonists for the treatment of MS and other demyelinating diseases can be shown
as
described in W02005/097098.
Demyelinating conditions are manifested in loss of myelin - the multiple dense
layers of
lipids and protein which cover many nerve fibers. These layers are provided by
oligodendroglia in the central nervous system (CNS), and Schwann cells in the
peripheral nervous system (PNS). In patients with demyelinating conditions,
demyelination may be irreversible; it is usually accompanied or followed by
axonal
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
degeneration, and often by cellular degeneration. Demyelination can occur as a
result
of neuronal damage or damage to the myelin itself - whether due to aberrant
immune
responses, local injury, ischemia, metabolic disorders, toxic agents, or viral
infections
(Prineas and McDonald, Demyelinating Diseases. In Greenfield's Neuropathology,
5 6th ed. (Edward Arnold: New York, 1997) 813-811, Beers and Berkow,
eds., The
Merck Manual of Diagnosis and Therapy, 17th ed. (Whitehouse Station,
N.J.:
Merck Research Laboratories, 1999) 1299, 1437, 1473-76, 1483).
Central demyelination (demyelination of the CNS) occurs in several conditions,
often of
uncertain etiology, that have come to be known as the primary demyelinating
diseases.
10 Of these, multiple sclerosis (MS) is the most prevalent. Other primary
demyelinating
diseases include adrenoleukodystrophy (ALD), adrenomyeloneuropathy, AIDS-
vacuolar myelopathy, HTLV-associated myelopathy, Leber's hereditary optic
atrophy,
progressive multifocal leukoencephalopathy (PML), subacute sclerosing
panencephalitis, Guillian-Barre syndrome and tropical spastic paraparesis. In
addition,
15 there are acute conditions in which demyelination can occur in the CNS,
e.g., acute
disseminated encephalomyelitis (ADEM) and acute viral encephalitis.
Furthermore,
acute transverse myelitis, a syndrome in which an acute spinal cord
transection of
unknown cause affects both gray and white matter in one or more adjacent
thoracic
segments, can also result in demyelination. Also, disorders in which myelin
forming
20 glial cells are damaged including spinal cord injuries, neuropathies and
nerve injury.
The present invention relates to compounds of the formula I suitable for
modulating the
activity of PPARs, especially the activity of PPARdelta and PPARalpha.
Depending on
the modulation profile, the compounds of the formula I are suitable for the
treatment,
control and prophylaxis of the indications described hereinafter, and for a
number of
other pharmaceutical applications connected thereto (see, for example, Berger,
J., et
al., Annu. Rev. Med., 2002, 53, 409-435; Wilson, T. et al., J. Med. Chem.,
2000, 43(4),
527-550; Kliewer, S. et al., Recent Prog Horm Res., 2001, 56, 239-63;
Fruchart, J.C. et
al., 2001, Pharmacological Research, 44(5), 345-52; Kersten, S. et al.,
Nature, 2000,
405, 421-424; Torra, I.P. et al., Curr Opin Lipidol, 2001,12, 245-254).
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
21
Compounds of this type are particularly suitable for the treatment and/or
prevention of:
1. - Disorders of fatty acid metabolism and glucose utilization disorders.
- Disorders in which insulin resistance is involved
2. Diabetes mellitus, especially type 2 diabetes, including the prevention of
the
sequelae associated therewith.
Particular aspects in this connection are
- hyperglycemia,
- improvement in insulin resistance,
- improvement in glucose tolerance,
- protection of the pancreatic 9 cells
- prevention of macro- and microvascular disorders
3. Dyslipidemias and their sequelae such as, for example, atherosclerosis,
coronary
heart disease, cerebrovascular disorders etc, especially those (but not
restricted
thereto) which are characterized by one or more of the following factors:
- high plasma triglyceride concentrations, high postprandial plasma
triglyceride
concentrations,
- low HDL cholesterol concentrations
- low ApoA lipoprotein concentrations
- high LDL cholesterol concentrations
- small dense LDL cholesterol particles
- high ApoB lipoprotein concentrations
4. Various other conditions which may be associated with the metabolic
syndrome,
such as:
- obesity (excess weight), including central obesity
- thromboses, hypercoagulable and prothrombotic states (arterial and venous)
- high blood pressure
- heart failure such as, for example (but not restricted thereto), following
myocardial infarction, hypertensive heart disease or cardiomyopathy
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
22
5. Disorders or conditions in which inflammatory reactions are involved:
- atherosclerosis such as, for example (but not restricted thereto), coronary
sclerosis including angina pectoris or myocardial infarction, stroke
- vascular restenosis or reocclusion
- chronic inflammatory bowel diseases such as, for example, Crohn's disease
and ulcerative colitis
- asthma
- lupus erythematosus (LE) or inflammatory rheumatic disorders such as, for
example, rheumatoid arthritis
- other inflammatory states
6. Disorders of cell cycle or cell differentiation processes:
- adipose cell tumors
- lipomatous carcinomas such as, for example, liposarcomas
- solid tumors and neoplasms such as, for example (but not restricted
thereto),
carcinomas of the gastrointestinal tract, of the liver, of the biliary tract
and of the
pancreas, endocrine tumors, carcinomas of the lungs, of the kidneys and the
urinary tract, of the genital tract, prostate carcinomas etc
- acute and chronic myeloproliferative disorders and lymphomas
- angiogenesis
7. Demyelinating and other neurodegenerative disorders of the central and
peripheral
nervous systems including:
- Alzheimer's disease
- multiple sclerosis
- Parkinson's disease
- adrenoleukodystrophy (ALD)
- adrenomyeloneuropathy
- AIDS-vacuolar myelopathy
- HTLV-associated myelopathy
- Leber's hereditary optic atrophy
- progressive multifocal leukoencephalopathy (PML)
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
23
- subacute sclerosing panencephalitis
- Guillian-Barre syndrome
- tropical spastic paraparesis
- acute disseminated encephalomyelitis (ADEM)
- acute viral encephalitis
- acute transverse myelitis
- spinal cord and brain trauma
- Charcot-Marie-Tooth disease
8. Skin disorders and/or disorders of wound healing processes:
- erythemato-squamous dermatoses such as, for example, psoriasis
- acne vulgaris
- other skin disorders and dermatological conditions which are modulated by
PPAR
- eczemas and neurodermitis
- dermatitis such as, for example, seborrheic dermatitis or photodermatitis
- keratitis and keratoses such as, for example, seborrheic keratoses, senile
keratoses, actinic keratosis, photo-induced keratoses or keratosis
follicularis
- keloids and keloid prophylaxis
- warts, including condylomata or condylomata acuminata
- human papilloma viral (HPV) infections such as, for example, venereal
papillomata, viral warts such as, for example, molluscum contagiosum,
leukoplakia
- papular dermatoses such as, for example, Lichen planus
- skin cancer such as, for example, basal-cell carcinomas, melanomas or
cutaneous T-cell lymphomas
- localized benign epidermal tumors such as, for example, keratoderma,
epidermal naevi
- chilblains
- wound healing
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
24
9. Other disorders
- high blood pressure
- pancreatitis
- syndrome X
- polycystic ovary syndrome (PCOS)
- asthma
- osteoarthritis
- lupus erythematosus (LE) or inflammatory rheumatic disorders such as, for
example, rheumatoid arthritis
- vasculitis
- wasting (cachexia)
- gout
- ischemia/reperfusion syndrome
- acute respiratory distress syndrome (ARDS)
Formulations
The amount of a compound of formula I necessary to achieve the desired
biological
effect depends on a number of factors, for example the specific compound
chosen, the
intended use, the mode of administration and the clinical condition of the
patient. The
daily dose is generally in the range from 0.001 mg to 100 mg (typically from
0.01 mg to
50 mg) per day and per kilogram of bodyweight, for example 0.1-10 mg/kg/day.
An
intravenous dose may be, for example, in the range from 0.001 mg to 1.0 mg/kg,
which
can suitably be administered as infusion of 10 ng to 100 ng per kilogram and
per
minute. Suitable infusion solutions for these purposes may contain, for
example, from
0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses
may contain,
for example, from 1 mg to 10 g of the active ingredient. Thus, ampules for
injections
may contain, for example, from 1 mg to 100 mg, and single-dose formulations
which
can be administered orally, such as, for example, capsules or tablets, may
contain, for
example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg. For the therapy
of the
abovementioned conditions, the compounds of formula I may be used as the
compound itself, but they are preferably in the form of a pharmaceutical
composition
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
with an acceptable carrier. The carrier must, of course, be acceptable in the
sense that
it is compatible with the other ingredients of the composition and is not
harmful for the
patient's health. The carrier may be a solid or a liquid or both and is
preferably
formulated with the compound as a single dose, for example as a tablet, which
may
5 contain from 0.05% to 95% by weight of the active ingredient. Other
pharmaceutically
active substances may likewise be present, including other compounds of
formula I.
The pharmaceutical compositions of the invention can be produced by one of the
known pharmaceutical methods, which essentially consist of mixing the
ingredients
with pharmacologically acceptable carriers and/or excipients.
Pharmaceutical compositions of the invention are those suitable for oral,
rectal, topical,
peroral (for example sublingual) and parenteral (for example subcutaneous,
intramuscular, intradermal or intravenous) administration, although the most
suitable
mode of administration depends in each individual case on the nature and
severity of
the condition to be treated and on the nature of the compound of formula I
used in
each case. Coated formulations and coated slow-release formulations also
belong
within the framework of the invention. Preference is given to acid- and
gastric juice-
resistant formulations. Suitable coatings resistant to gastric juice comprise
cellulose
acetate phthalate, polyvinyl acetate phthalate, hyd roxypropylmethylcellu lose
phthalate
and anionic polymers of methacrylic acid and methyl methacrylate.
Suitable pharmaceutical preparations for oral administration may be in the
form of
separate units such as, for example, capsules, cachets, suckable tablets or
tablets,
each of which contain a defined amount of the compound of formula I; as
powders or
granules, as solution or suspension in an aqueous or nonaqueous liquid; or as
an oil-
in-water or water-in-oil emulsion. These compositions may, as already
mentioned, be
prepared by any suitable pharmaceutical method which includes a step in which
the
active ingredient and the carrier (which may consist of one or more additional
ingredients) are brought into contact. The compositions are generally produced
by
uniform and homogeneous mixing of the active ingredient with a liquid and/or
finely
divided solid carrier, after which the product is shaped if necessary. Thus,
for example,
a tablet can be produced by compressing or molding a powder or granules of the
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
26
compound, where appropriate with one or more additional ingredients.
Compressed
tablets can be produced by tableting the compound in free-flowing form such
as, for
example, a powder or granules, where appropriate mixed with a binder, glidant,
inert
diluent and/or one (or more) surface-active/dispersing agent(s) in a suitable
machine.
Molded tablets can be produced by molding the compound, which is in powder
form
and is moistened with an inert liquid diluent, in a suitable machine.
Pharmaceutical compositions which are suitable for peroral (sublingual)
administration
comprise suckable tablets which contain a compound of formula I with a
flavoring,
normally sucrose and gum arabic or tragacanth, and pastilles which comprise
the
compound in an inert base such as gelatin and glycerol or sucrose and gum
arabic.
Pharmaceutical compositions suitable for parenteral administration comprise
preferably sterile aqueous preparations of a compound of formula I, which are
preferably isotonic with the blood of the intended recipient. These
preparations are
preferably administered intravenously, although administration may also take
place by
subcutaneous, intramuscular or intradermal injection. These preparations can
preferably be produced by mixing the compound with water and making the
resulting
solution sterile and isotonic with blood. Injectable compositions of the
invention
generally contain from 0.1 to 5% by weight of the active compound.
Pharmaceutical compositions suitable for rectal administration are preferably
in the
form of single-dose suppositories. These can be produced by mixing a compound
of
the formula I with one or more conventional solid carriers, for example cocoa
butter,
and shaping the resulting mixture.
Pharmaceutical compositions suitable for topical use on the skin are
preferably in the
form of ointment, cream, lotion, paste, spray, aerosol or oil. Carriers which
can be used
are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of
two or more
of these substances. The active ingredient is generally present in a
concentration of
from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
27
Transdermal administration is also possible. Pharmaceutical compositions
suitable for
transdermal uses can be in the form of single plasters which are suitable for
long-term
close contact with the patient's epidermis. Such plasters suitably contain the
active
ingredient in an aqueous solution which is buffered where appropriate,
dissolved
and/or dispersed in an adhesive or dispersed in a polymer. A suitable active
ingredient
concentration is about 1% to 35%, preferably about 3% to 15%. A particular
possibility
is for the active ingredient to be released by electrotransport or
iontophoresis as
described, for example, in Pharmaceutical Research, 2(6): 318 (1986).
The compounds of the formula I are distinguished by favorable effects on
metabolic
disorders. They beneficially influence lipid and sugar metabolism, in
particular they
lower the triglyceride level and are suitable for the prevention and treatment
of type II
diabetes and atheriosclerosis and the diverse sequalae thereof.
Combinations with other medicaments
The compounds of the invention can be administered alone or in combination
with one
or more further pharmacologically active substances. In particular, the
compounds of
the invention can be administered in combination with active ingredients
having a
similar pharmacological action. For example, they can be administered in
combination
with active ingredients which have favorable effects on metabolic disturbances
or
disorders frequently associated therewith. Examples of such medicaments are
1. medicaments which lower blood glucose, antidiabetics,
2. active ingredients for the treatment of dyslipidemias,
3. antiatherosclerotic medicaments,
4. antiobesity agents,
5. antiinflammatory active ingredients
6. active ingredients for the treatment of malignant tumors
7. antithrombotic active ingredients
8. active ingredients for the treatment of high blood pressure
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
28
9. active ingredients for the treatment of heart failure and
10. active ingredients for the treatment and/or prevention of complications
caused
by diabetes or associated with diabetes.
11. active ingredients for the treatment of neurodegenerative diseases
12. active ingredients for the treatment of disorders of the central nervous
system
13. active ingredients for the treatment of drug, nicotine and alcohol
addiction
14. analgesics
They can be combined with the compounds of the invention of the formula I in
particular for a synergistic enhancement of activity. Administration of the
active
ingredient combination can take place either by separate administration of the
active
ingredients to the patient or in the form of combination products in which a
plurality of
active ingredients are present in one pharmaceutical preparation.
Particularly suitable further active ingredients for the combination
preparations are:
All antidiabetics mentioned in the Rote Liste 2006, Chapter 12; all slimming
agents/appetite supressants mentioned in the Rote Liste 2006, Chapter 1; all
lipid-
lowering agents mentioned in the Rote Liste 2006, Chapter 58. They can be
combined
with the compound of the formula I according to the invention in particular
for a
synergistic enhancement of activity. The active compound combination can be
administered either by separate administration of the active compounds to the
patient
or in the form of combination preparations in which a plurality of active
compounds are
present in a pharmaceutical preparation. Most of the active compounds listed
below
are disclosed in USP Dictionary of USAN and International Drug Names, US
Pharmacopeia, Rockville 2001.
Antidiabetics include insulin and insulin derivatives, such as, for example,
Lantus (see
www.lantus.com) or HMR 1964 or those descibed in W02005005477 (Novo Nordisk),
fast-acting insulins (see US 6,221,633), inhalable insulins, such as, for
example,
Exubera or oral insulins, such as, for example, IN-105 (Nobex) or Oral-lynTM
(Generex Biotechnology), GLP-1 derivatives, such as, for example, Exenatide,
Liraglutide or those disclosed in WO 98/08871 or W02005027978 by Novo Nordisk
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
29
A/S, in WO 01/04156 by Zealand or in WO 00/34331 by Beaufour-Ipsen,
pramlintide
acetate (Symlin; Amylin Pharmaceuticals), and also orally effective
hypoglycemic
active ingredients.
The active compounds preferably include
sulfonylureas,
biguanidines,
meglitinides,
oxadiazolidinediones,
thiazolidinediones,
glucosidase inhibitors,
inhibitors of glycogen phosphorylase,
glucagon antagonists,
glucokinase activators,
inhibitors of fructose-l,6-bisphosphatase,
modulators of the glucose transporter 4 (GLUT4),
inhibitors of glutamine:fructose-6-phosphate amidotransferase (GFAT),
GLP-1 agonists,
potassium channel openers, such as, for example, those disclosed in WO
97/26265
and WO 99/03861 by Novo Nordisk A/S,
inhibitors of dipeptidylpeptidase IV (DPP-IV),
insulin sensitizers,
inhibitors of liver enzymes involved in the stimulation of gluconeogenesis
and/or
glycogenolysis,
modulators of glucose uptake, glucose transport and glucose backresorption,
inhibitors of 11f3-HSD1,
inhibitors of protein tyrosine phosphatase 1 B (PTP1 B),
modulators of the sodium/glucose cotransporter 1 or 2 (SGLT1, SGLT2),
compounds which alter lipid metabolism, such as antihyperlipidemic active
ingredients
and antilipidemic active ingredients,
compounds which reduce food intake or food absorption,
compounds which increase thermogenesis,
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
PPAR and RXR modulators and
active ingredients which act on the ATP-dependent potassium channel of the
beta
cells.
5 In one embodiment of the invention, the compound of the formula I is
administered in
combination with a HMGCoA reductase inhibitor, such as simvastatin,
fluvastatin,
pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin or L-659699.
In one embodiment of the invention, the compound of the formula I is
administered in
10 combination with a cholesterol resorption inhibitor, such as, for example,
ezetimibe,
tiqueside, pamaqueside, FM-VP4 (sitostanol/campesterol ascorbyl phosphate;
Forbes
Medi-Tech, W02005042692), MD-0727 (Microbia Inc., W02005021497) or with
compounds as described in W02002066464 (Kotobuki Pharmaceutical Co. Ltd.),
W02005062824 (Merck & Co.) or W02005061451 and W02005061452 (AstraZeneca
15 AB).
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a PPAR gamma agonist, such as, for example, rosiglitazone,
pioglitazone, JTT-501, GI 262570, R-483 or CS-011 (rivoglitazone).
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a PPAR alpha agonist, such as, for example, GW9578, GW-
590735,
K-111, LY-674, KRP-101 or DRF-10945.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a mixed PPAR alpha/gamma agonist, such as, for example,
muraglitazar, tesaglitazar, naveglitazar, LY-510929, ONO-5129, E-3030 or as
described in W000/64888, W000/64876, W003/020269, W02004075891,
W02004076402, W02004075815, W02004076447, W02004076428,
W02004076401, W02004076426, W02004076427, W02006018118,
W02006018115, and W02006018116 or in J.P. Berger et al., TRENDS in
Pharmacological Sciences 28(5), 244-251, 2005.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
31
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a PPAR delta agonist, such as, for example, GW-501516 or as
described in W02005097762, W02005097786, W02005097763, and
W02006029699.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with metaglidasen or with MBX-2044 or other partial PPAR gamma
agonists/antagonists.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a fibrate, such as, for example, fenofibrate, clofibrate or
bezafibrate.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an MTP inhibitor, such as, for example, implitapide, BMS-
201038, R-
103757 or those described in W02005085226.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a CETP inhibitor, such as, for example, torcetrapib or JTT-
705.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a bile acid resorption inhibitor (see, for example, US
6,245,744, US
6,221,897 or W000/61568), such as, for example, HMR 1741 or those described in
DE
10 2005 033099.1 and DE 10 2005 033100.9.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a polymeric bile acid adsorber, such as, for example,
cholestyramine
or colesevelam.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an LDL receptor inducer (see US 6,342,512), such as, for
example,
HMR1171, HMR1586 or those described in W02005097738.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
32
In one embodiment, the compound of the formula I is administered in
combination with
OmacorO (omega-3 fatty acids; highly concentrated ethyl esters of
eicosapentaenoic
acid and docosahexaenoic acid).
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an ACAT inhibitor, such as, for example, avasimibe.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an antioxidant, such as, for example, OPC-14117, probucol,
tocopherol, ascorbic acid, f3-carotene or selenium.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a vitamin, such as, for example, vitamin B6 or vitamin B12.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a lipoprotein lipase modulator, such as, for example,
ibrolipim (NO-
1886).
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an ATP-citrate lyase inhibitor, such as, for example, SB-
204990.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a squalene synthetase inhibitor, such as, for example, BMS-1
88494
or as described in W02005077907.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a lipoprotein(a) antagonist, such as, for example, gemcabene
(Cl-
1027).
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an HM74A receptor agonists, such as, for example, nicotinic
acid.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
33
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a lipase inhibitor, such as, for example, orlistat or
cetilistat (ATL-962).
In one embodiment of the invention, the compound of the formula I is
administered in
combination with insulin.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a sulfonylurea, such as, for example, tolbutamide,
glibenclamide,
glipizide or glimepiride.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a biguanide, such as, for example, metformin.
In another embodiment of the invention, the compound of the formula I is
administered
in combination with a meglitinide, such as, for example, repaglinide or
nateglinide.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with a thiazolidinedione, such as, for example, troglitazone,
ciglitazone,
pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 by Dr.
Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-
2-
quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an a-glucosidase inhibitor, such as, for example, miglitol or
acarbose.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an active ingredient which acts on the ATP-dependent
potassium
channel of the beta cells, such as, for example, tolbutamide, glibenclamide,
glipizide,
glimepiride or repaglinide.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with more than one of the compounds mentioned above, for example
in
combination with a sulfonylurea and metformin, a sulfonylurea and acarbose,
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
34
repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin,
insulin
and troglitazone, insulin and lovastatin, etc.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an inhibitor of glycogen phosphorylase, such as, for example,
PSN-
357 or FR-258900 or those described in W02003084922, W02004007455,
W02005073229-31 or W02005067932.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with glucagon receptor antagonists, such as, for example, A-
770077,
NNC-25-2504 or such as in W02004100875 or W02005065680.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with activators of glucokinase, such as, for example, RO-4389620,
LY-
2121260 (W02004063179), PSN-105, PSN-110, GKA-50 or those described, for
example, by Prosidion in W02004072031, W02004072066, WO 05103021 or WO
06016178, by Roche in WO 00058293, WO 00183465, WO 00183478, WO 00185706,
WO 00185707, WO 01044216, GB 02385328, WO 02008209, WO 02014312, WO
0246173, WO 0248106, DE 10259786, WO 03095438, US 04067939 or WO
04052869, by Novo Nordisk in EP 1532980, WO 03055482, WO 04002481, WO
05049019, WO 05066145 or WO 05123132, by Merck/Banyu in WO 03080585,
W003097824, WO 04081001, WO 05063738 or WO 05090332, by Eli Lilly in WO
04063194, or by Astra Zeneca in WO 01020327, WO 03000262, WO 03000267, WO
03015774, WO 04045614, WO 04046139, WO 05044801, WO 05054200, WO
05054233, WO 05056530, WO 05080359, WO 05080360 or WO 05121110.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an inhibitor of gluconeogenesis, such as, for example, FR-
225654.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with inhibitors of fructose-l,6-bisphosphatase (FBPase), such as,
for
example, CS-917.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
In one embodiment of the invention, the compound of the formula I is
administered in
combination with modulators of the glucose transporter 4 (GLUT4), such as, for
example, KST-48 (D.-O. Lee et al.: Arzneim.-Forsch. Drug Res. 54 (12), 835
(2004)).
5 In one embodiment of the invention, the compound of the formula I is
administered in
combination with inhibitors of glutamine:fructose-6-phosphate amidotransferase
(GFAT), as described, for example, in W02004101528.
In one embodiment of the invention, the compound of the formula I is
administered in
10 combination with inhibitors of dipeptidylpeptidase IV (DPP-IV), such as,
for example,
vildagliptin (LAF-237), sitagliptin (MK-0431), saxagliptin ((BMS-477118), GSK-
823093,
PSN-9301, SYR-322, SYR-619, TA-6666, TS-021, GRC-8200, GW-825964X or as
described in W02003074500, W02003106456, W0200450658, W02005058901,
W02005012312, W02005/012308, PCT/EP2005/007821, PCT/EP2005/008005,
15 PCT/EP2005/008002, PCT/EP2005/008004, PCT/EP2005/008283, DE 10 2005
012874.2 or DE 10 2005 012873.4.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 (119-
HSD1),
20 such as, for example, BVT-2733 or those described, for example, in
W0200190090-
94, W0200343999, W02004112782, W0200344000, W0200344009,
W02004112779, W02004113310, W02004103980, W02004112784,
W02003065983, W02003104207, W02003104208, W02004106294,
W02004011410, W02004033427, W02004041264, W02004037251,
25 W02004056744, W02004065351, W02004089367, W02004089380,
W02004089470-71, W02004089896, W02005016877 or W02005097759.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with inhibitors of protein tyrosine phosphatase 1 B (PTP1 B), as
described,
30 for example, in W0200119830-31, W0200117516, W02004506446, W02005012295,
PCT/EP2005/00531 1, PCT/EP2005/005321, PCT/EP2005/007151, PCT/EP2005/ or
DE 10 2004 060542.4.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
36
In one embodiment of the invention, the compound of the formula I is
administered in
combination with modulators of the sodium/glucose cotransporter 1 or 2 (SGLT1,
SGLT2), such as, for example, KGA-2727, T-1095 and SGL-0010 or as described,
for
example, in W02004007517, W0200452903, W0200452902, W02005121161 ,
W02005085237, JP2004359630 or by A. L. Handlon in Expert Opin. Ther. Patents
(2005) 15(11), 1531-1540.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with inhibitors of hormone-sensitive lipase (HSL), such as those
described, for example, in WO01/17981, WO01/66531, W02004035550,
W02005073199 or W003/051842.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with inhibitors of acetyl-CoA carboxylase (ACC) such as those
described,
for example, in W0199946262, W0200372197, W02003072197 or W02005044814.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an inhibitor of phosphoenolpyruvate carboxykinase (PEPCK),
such
as those described, for example, in W02004074288.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an inhibitor of glycogen synthase kinase-3 beta (GSK-3 beta),
such
as those described, for example, in US2005222220, W02004046117,
W02005085230, W02005111018, W02003078403, W02004022544,
W02003106410, W02005058908, US2005038023, W02005009997, US2005026984,
W02005000836, W02004106343, EP1460075, W0200401491 0, W02003076442,
W02005087727 or W02004046117.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an inhibitor of protein kinase C beta (PKC beta), such as,
for
example, ruboxistaurin.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
37
In one embodiment of the invention, the compound of the formula I is
administered in
combination with an endothelin-A receptor antagonist, such as, for example,
avosentan (SPP-301).
In one embodiment of the invention, the compound of the formula I is
administered in
combination with inhibitors of "I-kappaB kinase" (IKK inhibitors), such as
those
described, for example, in W02001000610, W02001030774, W02004022553 or
W02005097129.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with modulators of the glucocorticoid receptor as described, for
example,
in W02005090336.
In a further embodiment of the invention, the compound of the formula I is
administered in combination with CART modulators (see "Cocaine-amphetamine-
regulated transcript influences energy metabolism, anxiety and gastric
emptying in
mice" Asakawa, A. et al.: Hormone and Metabolic Research (2001), 33(9), 554-
558);
NPY antagonists such as, for example, {4-[(4-aminoquinazolin-2-ylamino)methyl]-
cyclohexylmethyl}naphthalene-l-sulfonamide hydrochloride (CGP 71683A);
peptide YY 3-36 (PYY3-36) or analogous compounds, such as, for example, CJC-
1682
(PYY3-36 conjugated with human serum albumin via Cys34), CJC-1643 (derivative
of
PYY3-36 which conjugates in vivo to serum albumin) or those described in
W02005080424;
cannabinoid receptor 1 antagonists, such as, for example, rimonabant, SR147778
or
those described, for example, in EP 0656354, WO 00/15609, WO 02/076949,
W02005080345, W02005080328, W02005080343, W02005075450,
W02005080357, W0200170700, W02003026647-48, W0200302776,
W02003040107, W02003007887, W02003027069, US6,509,367, W0200132663,
W02003086288, W02003087037, W02004048317, W02004058145,
W02003084930, W02003084943, W02004058744, W02004013120,
W02004029204, W02004035566, W02004058249, W02004058255,
W02004058727, W02004069838, US20040214837, US20040214855,
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
38
US20040214856, W02004096209, W02004096763, W02004096794,
W02005000809, W02004099157, US20040266845, W02004110453,
W02004108728, W02004000817, W02005000820, US20050009870,
W0200500974, W02004111033-34, W0200411038-39, W02005016286,
W020050071 11, W02005007628, US20050054679, W02005027837,
W02005028456, W02005063761-62, W02005061509 or W02005077897;
MC4 agonists (for example [2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-
pyrazolo[4,3-c]pyrid in-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]-1-amino-1,2,3,4-
tetrahydro-
naphthalene-2-carboxamide; (WO 01/91752)) or LB53280, LB53279, LB53278 or
THIQ, MB243, RY764, CHIR-785, PT-141 or those described in W02005060985,
W02005009950, W02004087159, W02004078717, W02004078716,
W02004024720, US20050124652, W02005051391, W02004112793,
WOUS20050222014, US20050176728, US20050164914, US20050124636,
US20050130988, US20040167201, W02004005324, W02004037797,
W02005042516, W02005040109, W02005030797, US20040224901,
W0200501921, W0200509184, W02005000339, EP1460069, W02005047253,
W02005047251, EP1538159, W02004072076, W02004072077 or W02006024390;
orexin receptor antagonists (for example 1-(2-methylbenzoxazol-6-yl)-3-
[1,5]naphthyridin-4-ylurea hydrochloride (SB-334867-A) or those described, for
example, in W0200196302, W0200185693, W02004085403 or W02005075458);
histamine H3 receptor agonists (for example 3-cyclohexyl-1-(4,4-dimethyl-
1,4,6,7-
tetrahydroimidazo[4,5-c]pyridin-5-yl)-propan-1-one oxalic acid salt (WO
00/63208) or
those described in W0200064884, W02005082893);
CRF antagonists (for example [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-
triazafluoren-4-yl]dipropylamine (WO 00/66585));
CRF BP antagonists (for example urocortin);
urocortin agonists;
[33 agonists (such as, for example, 1-(4-chloro-3-methanesulfonylmethylphenyl)-
2-[2-
(2,3-dimethyl-1H-indol-6-yloxy)ethylamino]ethanol hydrochloride (WO
01/83451));
MSH (melanocyte-stimulating hormone) agonists;
MCH (melanin-concentrating hormone) receptor antagonists (such as, for
example,
NBI-845, A-761, A-665798, A-798, ATC-0175, T-226296, T-71, GW-803430 or those
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
39
compounds described in W02003/15769, W02005085200, W02005019240,
W02004011438, W02004012648, W02003015769, W02004072025,
W02005070898, W02005070925, W02006018280, W02006018279,
W02004039780, W02003033476, W02002006245, W02002002744,
W02003004027 or FR2868780);
CCK-A agonists (such as, for example, {2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-
(2-
cyclohexylethyl)-thiazol-2-ylcarbamoyl]-5,7-dimethylindol-1-yl}acetic acid
trifluoroacetic
acid salt (WO 99/15525), SR-146131 (WO 0244150) or SSR-125180);
serotonin reuptake inhibitors (for example dexfenfluramine);
mixed serotonin- and noradrenergic compounds (for example WO 00/71549);
5-HT receptor agonists, for example 1-(3-ethylbenzofuran-7-yl)piperazine
oxalic acid
salt (WO 01/09111);
5-HT2C receptor agonists (such as, for example, APD-356, BVT-933 or those
described in W0200077010, W020077001-02, W02005019180, W02003064423,
W0200242304 or W02005082859);
5-HT6 receptor antagonists, such as described, for example, in W02005058858;
bombesin receptor agonists (BRS-3 agonists);
galanin receptor antagonists;
growth hormone (for example human growth hormone or AOD-9604);
growth hormone releasing compounds (tert-butyl 6-benzyloxy-l-(2-
diisopropylamino-
ethylcarbamoyl)-3,4-dihydro-1 H-isoquinoline-2-carboxylate (WO 01/85695));
growth hormone secretagog receptor antagonists (ghrelin antagonists) such as,
for
example, A-778193 or those described in W02005030734;
TRH agonists (see, for example, EP 0 462 884);
uncoupling protein 2 or 3 modulators;
leptin agonists (see for example Lee, Daniel W.; Leinung, Matthew C.;
Rozhavskaya-
Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to
the
treatment of obesity. Drugs of the Future (2001), 26(9), 873-881);
DA agonists (bromocriptine or Doprexin);
lipase/amylase inhibitors (as described, for example, in WO 00/40569);
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
inhibitors of diacylglycerol 0-acyltransferases (DGATs) such as described, for
example, in US2004/0224997, W02004094618, W0200058491, W02005044250,
W02005072740, JP2005206492 or W02005013907;
inhibitors of fatty acid synthase (FAS) such as, for example, C75 or those
described in
5 W02004005277;
oxyntomodulin;
oleoyl-estrone
or thyroid hormone receptor agonists, such as, for example, KB-2115 or those
10 described in W020058279, W0200172692, W0200194293, W02003084915,
W02004018421 or W02005092316.
In one embodiment of the invention, the further active ingredient is leptin;
see for example "Perspectives in the therapeutic use of leptin", Salvador,
Javier;
15 Gomez-Ambrosi, Javier; Fruhbeck, Gema, Expert Opinion on Pharmacotherapy
(2001), 2(10), 1615-1622.
In one embodiment of the invention, the further active ingredient is
dexamphetamine or
amphetamine.
20 In one embodiment of the invention, the further active ingredient is
fenfluramine or
dexfenfluramine.
In another embodiment of the invention, the further active ingredient is
sibutramine.
In one embodiment of the invention, the further active ingredient is mazindol
or
phentermine.
In one embodiment, the compounds of the formula I are administered in
combination
with bulking agents, preferably insoluble bulking agents (see, for example,
carob/Caromax (Zunft H J; et al., Carob pulp preparation for treatment of
hypercholesterolemia, ADVANCES IN THERAPY (2001 Sep-Oct), 18(5), 230-6).
Caromax is a carob-containing product from Nutrinova, Nutrition Specialties &
Food
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
41
Ingredients GmbH, Industriepark Hochst, 65926 Frankfurt/Main). Combination
with
Caromax is possible in one preparation or by separate administration of
compounds
of the formula I and Caromax . Caromax can in this connection also be
administered
in the form of food products such as, for example, in bakery products or
muesli bars.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with PDE (phosphodiesterase) inhibitors, as described, for
example, in
W02003/077949 or W02005012485.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with NAR-1 (nicotinic acid receptor) agonists as described, for
example, in
W02004094429.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with CB2 (cannabinoid receptor) agonists as described, for
example, in
US2005/143448.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with histamine 1 agonists as described, for example, in
W02005101979.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with bupropion, as described in W02006017504.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with opioid antagonists as described, for example, in W02005107806
or
W02004094429.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with neutral endopeptidase inhibitors as described, for example,
in
W0200202513, W02002/06492, WO 2002040008, W02002040022 or
W02002047670.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
42
In one embodiment of the invention, the compound of the formula I is
administered in
combination with NPY inhibitors (neuropeptide Y) as described, for example, in
W02002047670.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with sodium/hydrogen exchange inhibitors as described, for
example, in
W02003092694.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with modulators of the glucocorticoid receptor as described, for
example,
in W02005090336.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with nicotine receptor agonists as described, for example, in
W02004094429.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with NRIs (norepinephrine reuptake inhibitors) as described, for
example,
in W02002053140.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with MOA (E-beta-methoxyacrylate), such as, for example, segeline,
or as
described, for example, in W02002053140.
In one embodiment of the invention, the compound of the formula I is
administered in
combination with antithrombotic active ingredients, such as, for example,
clopidrogel.
It is to be understood that each suitable combination of the compounds
according to
the invention with one or more of the compounds mentioned above and optionally
one
or more further pharmacologically active substances is meant to be included in
the
scope of the present invention.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
43
The formulae for some of the development codes mentioned above are given
below.
R = CH,; CH=-CH3
H N O O
o
H Fi
HoWHOO- 0 NH
0 O O H 0
O
Na Na
FM-VP4 JTT-501
0
CH'
H 0 / O N\
No I H \ N
0 OS
G1262570
CS-011
Rivoglitazone
0
HO~S I \ ~ ~
/\ v N NO CI Ci
H OH
J\
GW-9578 CI ~ O
K-111
0
Nz~ N, F
HO I ~ N4 I/ I ~ O H O
O H O O OH
0
LY-674 KRP-101
0
O a~O OH O F F
S/ OHO~O / I S I~ F
~
SN
LY-510929 GW-501516
CI
F F p
F g ~ N O O
F F H N ~=.io
F~N 0
N
Cr O ON, R
_
-103757 n
\
BMS-201038 ~ N
N
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
44
H3C
H3C H3C CH3 \
S~O O \JN I / O
H
OH HNjt'-~N
O \ \ I OPC-14117
JTT-705
Br
0 CI
H I\ ~~ CH3 O M
OCH3 CI OH
I I P
"IC~
N SB-204990 HO
NO-1886
0
HO, //
I\ / I S\p H3C\ CH3 OH
O O' X p
p P~ CH3 OH O CH
p I H3C IOI CH3 H3C 3
0/O O
BMS-188494 ~ ?II( CH3 H3C CH3
0 CI-1027
N 0 HO HO~~O p
Q I p / \
0 O ~OH I / OH
ATL-962 FR-258900 p
N
~ ~ / \ I Ns
H
HO , N
~ NNC-25-2504
~/ ~ NH LY-2121260
" o
O OH
3OflOH
p O I\ H Hp =
/ GKA-50 \O Q H OH
O
~~Oi Ho H O
= FR-225654
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
CI-- CI
O H H H
-c CI NH
O N
KST-48 CI N~ 0 HO
BMS-477118
N H-Cl O / O
0 0 N N v O~ O
O O O OH
H S HO,.. H
BVT-2733 HO OH
CI T-1095
i I
HN,,,
0~ O
O HN O
\ N
N
I\ N NH N~N
O
N / OoS \
N / THIQ
SPP-301 , CI
rN N
HN
0 HN O O HN O
N
x NH N NH
/7C\
O
/ I / I
O RY764 \
MB243 \
F F
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
46
MeO 0
F H ~ N I I
I/ O O F
H NH '
N O
CHIR-785 O A-761
O N H
< O N~!N~
O NH INI / /
F N
CI \ \ ~ H
A-665798 I / F
0 0 ATC-0175
NN
0 ioo
H
F \
I / T-226296
H
O NH2 NuNHZ
INIH
H2N N0N ,H NiN N~N N OH
H H
O H NH ~~ O SH O" NH
NxNHz HS O O O H H N~~ N N~~ N NFi
, O H O
O H
0 H HN O HO
\ I / ~ HO~ HO N HO 0
S q
CI ~_~ ~ ~ NJ HO O I j O\ I
AOD-9604
GW-803430 HO
/) CI
\ 0
/ NH ~
~ A-778193
NHZ C75
N ~
OH
H N~N ~ \ O 0
Z
O
H
I \ _ :
0
H Fi
O ~
oleoyl-ostrone
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
47
CI
O 0
HO CI OH
KB-2115
The activity of the compounds was tested as follows:
Determination of EC50 values of PPAR agonists in the cellular PPARalpha assay
Principle
The potency of substances which bind to human PPARalpha and activate it in an
agonistic manner is analyzed using a stably transfected HEK cell line (HEK=
human
embryo kidney) which is referred to here as PPARalpha reporter cell line. It
contains
two genetic elements, a luciferase reporter element (pdeltaM-GAL4-Luc-Zeo) and
a
PPARalpha fusion protein (GR-GAL4-humanPPARalpha-LBD) which mediates
expression of the luciferase reporter element depending on a PPARalpha ligand.
The
stably and constitutively expressed fusion protein GR-GAL4-humanPPARalpha-LBD
binds in the cell nucleus of the PPARalpha reporter cell line via the GAL4
protein
portion to the GAL4 DNA binding motifs 5'-upstream of the luciferase reporter
element
which is stably integrated in the genome of the cell line. There is only weak
expression
of the luciferase reporter gene in the absence of a PPARalpha ligand if fatty
acid-
depleted fetal calf serum (cs-FCS) is used in the assay. PPARalpha ligands
bind and
activate the PPARalpha fusion protein and thereby stimulate the expression of
the
luciferase reporter gene. The luciferase which is formed can be detected by
means of
chemiluminescence via an appropriate substrate.
Construction of the PPARalpha reporter cell line
The PPARalpha reporter cell line was prepared in two stages. Firstly, the
luciferase
reporter element was constructed and stably transfected into HEK cells. For
this
purpose, five binding sites of the yeast transcription factor GAL4 (Accession
#
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
48
AF264724) were cloned in 5'-upstream of a 68 bp-long minimal MMTV promoter
(Accession # V01175). The minimal MMTV promoter section contains a CCAAT box
and a TATA element in order to enable efficient transcription by RNA
polymerase II.
The cloning and sequencing of the GAL4-MMTV construct took place in analogy to
the
description of Sambrook J. et. al. (Molecular cloning, Cold Spring Harbor
Laboratory
Press, 1989). Then the complete Photinus pyralis gene (Accession # M15077) was
cloned in 3'-downstream of the GAL4-MMTV element. After sequencing, the
luciferase
reporter element consisting of five GAL4 binding sites, MMTV promoter and
luciferase
gene was recioned into a plasmid which confers zeocin resistance in order to
obtain
the plasmid pdeltaM-GAL4-Luc-Zeo. This vector was transfected into HEK cells
in
accordance with the statements in Ausubel, F.M. et al. (Current protocols in
molecular
biology, Vol. 1-3, John Wiley & Sons, Inc., 1995). Then zeocin-containing
medium (0.5
mg/mI) was used to select a suitable stable cell clone which showed very low
basal
expression of the luceriferase gene.
In a second step, the PPARalpha fusion protein (GR-GAL4-humanPPARalpha-LBD
was introduced into the stable cell clone described. For this purpose,
initially the cDNA
coding for the N-terminal 76 amino acids of the glucocorticoid receptor
(Accession #
P04150) was linked to the cDNA section coding for amino acids 1-147 of the
yeast
transcription factor GAL4 (Accession # P04386). The cDNA of the ligand-binding
domain of the human PPARalpha receptor (amino acids S167-Y468; Accession #
S74349) was cloned in at the 3'-end of this GR-GAL4 construct. The fusion
construct
prepared in this way (GR-GAL4-humanPPARalpha-LBD) was recloned into the
plasmid pcDNA3 (Invitrogen) in order to enable constitutive expression therein
by the
cytomegalovirus promoter. This plasmid was linearized with a restriction
endonuclease
and stably transfected into the previously described cell clone containing the
luciferase
reporter element. The finished PPARalpha reporter cell line which contains a
luciferase
reporter element and constitutively expresses the PPARalpha fusion protein (GR-
GAL4-human PPARalpha-LBD) was isolated by selection with zeocin (0.5 mg/mI)
and
G418 (0.5 mg/mI).
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
49
Assay procedure
The activity of PPARalpha agonists is determined in a 3-day assay which is
described
below:
Day 1
The PPARalphareporter cell line is cultivated to 80% confluence in DMEM (#
41965-
039, Invitrogen) which is mixed with the following additions: 10% cs-FCS
(fetal calf
serum; #SH-30068.03, Hyclone), 0.5 mg/mI zeocin (#R250-01, Invitrogen), 0.5
mg/mI
G418 (#10131-027, Invitrogen), 1% penicillin-streptomycin solution (#15140-
122,
lnvitrogen) and 2 mM L-glutamine (#25030-024, Invitrogen). The cultivation
takes
place in standard cell culture bottles (# 353112, Becton Dickinson) in a cell
culture
incubator at 37 C in the presence of 5% CO2. The 80%-confluent cells are
washed
once with 15 ml of PBS (#14190-094, lnvitrogen), treated with 3 ml of trypsin
solution
(#25300-054, Invitrogen) at 37 C for 2 min, taken up in 5 ml of the DMEM
described
and counted in a cell counter. After dilution to 500.000 cells/mI, 35,000
cells are
seeded in each well of a 96 well microtiter plate with a clear plastic base
(#3610,
Corning Costar). The plates are incubated in the cell culture incubator at 37
C and 5%
CO2 for 24 h.
Day 2
PPARalpha agonists to be tested are dissolved in DMSO in a concentration of 10
mM.
This stock solution is diluted in DMEM (#41965-039, Invitrogen) which is mixed
with
5% cs-FCS (#SH-30068.03, Hyclone), 2 mM L-glutamine (#25030-024, Invitrogen)
and
the previously described antibiotics (zeocin, G418, penicillin and
streptomycin).
Test substances are tested in 11 different concentrations in the range from 10
pM to
100 pM. More potent compounds are tested in concentration ranges from 1 pM to
10 pM or between 100 nM and 1 pM.
The medium of the PPARalpha reporter cell line seeded on day 1 is completely
removed by aspiration, and the test substances diluted in medium are
immediately
added to the cells. The dilution and addition of the substances is carried out
by a robot
(Beckman FX). The final volume of the test substances diluted in medium is 100
NI per
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
well of a 96 well microtiter plate. The DMSO concentration in the assay is
less than 0.1
% v/v in order to avoid cytotoxic effects of the solvent.
Each plate was charged with a standard PPARalpha agonist, which was likewise
diluted in 11 different concentrations, in order to demonstrate the
functioning of the
5 assay in each individual plate. The assay plates are incubated in an
incubator at 37 C
and 5% CO2 for 24 h.
Day 3
The PPARalpha reporter cells treated with the test substances are removed from
the
10 incubator, and the medium is aspirated off. The cells are lyzed by
pipetting 50 NI of
Bright Gio reagent (from Promega) into each well of a 96 well microtiter
plate. After
incubation at room temperature in the dark for 10 minutes, the microtiter
plates are
measured in the luminometer (Trilux from Wallac). The measuring time for each
well of
a microtiter plate is 1 sec.
Evaluation
The raw data from the luminometer are transferred into a Microsoft Excel file.
Dose-
effect plots and EC50 values of PPAR agonists are calculated using the XL.Fit
program as specified by the manufacturer (IDBS).
The PPARalpha EC50 values for the compounds of Examples 1 to 41 in this assay
are
in the range from 50 nM to >10 pM. Compounds of the invention of the formula I
activate the PPARalpha receptor.
Determination of EC50 values of PPAR agonists in the cellular PPARdelta assay
Principle
The potency of substances which bind to human PPARdelta and activate it in an
agonistic manner is analyzed using a stably transfected HEK cell line (HEK=
human
embryo kidney) which is referred to here as PPARdelta reporter cell line. In
analogy to
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
51
the assay described for PPARaIpha, the PPARdelta reporter cell line also
contains two
genetic elements, a luciferase reporter element (pdeltaM-GAL4-Luc-Zeo) and a
PPARdelta fusion protein (GR-GAL4-humanPPARdelta-LBD) which mediates
expression of the luciferase reporter element depending on a PPARdelta ligand.
The
stably and constitutively expressed fusion protein GR-GAL4-humanPPARdelta-LBD
binds in the cell nucleus of the PPARdelta reporter cell line via the GAL4
protein
portion to the GAL4 DNA binding motifs 5'-upstream of the luciferase reporter
element
which is stably integrated in the genome of the cell line. There is only
little expression
of the luciferase reporter gene in the absence of a PPARdelta ligand if fatty
acid-
depleted fetal calf serum (cs-FCS) is used in the assay. PPARdelta ligands
bind and
activate the PPARdelta fusion protein and thereby stimulate expression of the
luciferase reporter gene. The luciferase which is formed can be detected by
means of
chemiluminescence via an appropriate substrate.
Construction of the PPARdelta reporter cell line
The production of the stable PPARdelta reporter cell line is based on a stable
HEK-cell
clone which was stably transfected with a luciferase reporter element. This
step was
already described above in the section "construction of the PPARalpha reporter
cell
line". In a second step, the PPARdelta fusion protein (GR-GAL4-humanPPARdelta-
LBD was stably introduced into this cell clone. For this purpose, the cDNA
coding for
the N-terminal 76 amino acids of the glucocorticoid receptor (Accession #
P04150)
was linked to the cDNA section coding for amino acids 1-147 of the yeast
transcription
factor GAL4 (Accession # P04386). The cDNA of the ligand-binding domain of the
human PPARdelta receptor (amino acids 5139-Y441; Accession # L07592) was
cloned in at the 3'-end of this GR-GAL4 construct. The fusion construct
prepared in
this way (GR-GAL4-humanPPARdelta-LBD) was recloned into the plasmid pcDNA3
(Invitrogen) in order to enable constitutive expression by the cytomegalovirus
promoter. This plasmid was linearized with a restriction endonuclease and
stably
transfected into the previously described cell clone containing the luciferase
reporter
element. The resulting PPARdelta reporter cell line which contains a
luciferase reporter
element and constitutively expresses the PPARdelta fusion protein (GR-GAL4-
human
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
52
PPARdelta-LBD) was isolated by selection with zeocin (0.5 mg/mI) and G418
(0.5 mg/mI).
Assay procedure and evaluation
The activity of PPARdelta agonists is determined in a 3-day assay in exact
analogy to
the procedure already described for the PPARalpha reporter cell line except
that the
PPARdelta reporter cell line and a specific PPARdelta agonist was used as a
standard
to control test efficacy.
PPARdelta EC50 values in the range from 1 nM to >10 pM were measured for the
PPAR agonists of Examples 1 to 41 described in this application. Compounds of
the
invention of the formula I activate the PPARdelta receptor.
The examples given in Table II serve to illustrate the invention, but without
limiting it.
Table I
R6 N R5 ::::
\ R7 X NO
where R2, R3, R4 = H,
a dotted line means the point of attachment
If R6 and R7 are bonded to form an annelated ring together with the oxazole
respectively the thiazole ring, the upper dotted line means the point of
attachment for
R6 and the lower dotted line the point of attachment for R7.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
53
ExampleX U RI R5 R6 R7
1 -CH2CH2- 0 H -(CH2)3CH3
~ ,.=
2 -CH2CH2- S H -(CH2)3CH3
~,.=
3 CH2CH2- S H -(CH2)3CH3 ~-. /
4 -CH2CH2- S H -(CH2)3CH3
/ -.
-CH2CH2- S -CH3 -(CH2)3CH3 ~
ci
/'-=
6 -CH2CH2- S -CH3 -(CH2)3CH3 F ~- "
F
F
/''-
7 CH2CH2- S CH3 F ~
F
F
/
8 CH2CH2- S CH3 F ~-
F
F
/''-
9 CH2CH2- S CH3 '~ F ~
F
F
/''-
CH2CH2- S CH3 F ~.-"
F
F
11 CH2- 0 H -(CH2)3CH3
~ ,.=
12 CH2- S H -(CH2)3CH3
/ .
13 CH2- S H -(CH2)3CH3 ~
ci
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
54
ExampleX U R1 R5 R6 R7
14 CH2CH2- S -CH3 -(CH2)3-O-CH3 F
F
F
-(CH2)2-0-(CH2)2- /
15 -CH2CH2- S -CH3 F ~
O-CH3 F F
='-
16 -CH2CH2- S -CH3 N~z F
F
/ =' -
17 -CH2CH2- S -CH3 -(CH2)2-O-CH3 F
F
F
18 -CH2CH2- S H -(CH2)3CH3 ao H
19 -CH2CH2- S H -(CH2)3CH3 H
20 CH2CH2- S H -(CH2)3-O-CH3 H
21 -CH2CH2- S H -(CH2)2-0-(CH2)2- ci 0 H
O-CH3
22 -CH2CH2- S H H
23 CH2CH2- S H -(CH2)2-O-CH3 H
24 -CH2- S F -(CH2)3CH3 F
F
F
ci / =,
25 CH2- S F -(CH2)3CH3 ~
F ~
/ 26 -CH2- S F
F
F
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
Example U R1 R5 R6 R7
/ '=
F
27 -CH2- S F
F
F
/ =
28 -CH2- S F -(CH2)2-O-CH3 F \
F
F
=, ~~ /'
='
\
29 CH2- S F " F
F
F
./~ ~
30 -CH2- S F " F
O F
F
/ /==.
31 CH2- S F " F
F
/ '=
F \
32 -CH2- S -CF3 "
F
F
/ =' -
33 CH2- S CF3 F \--
F
F
/ 34 CH2- S CF3 -(CH2)2-O-CH3 F \
F
F
F \..-
35 CH2- S CF3 "
F
F
F
36 CH2- S CF3 "
O F
F
/ /=.
37 CH2- S CF3 " F \--
F
F
38 -CH2- S H -(CH2)3CH3 0~\ --- H
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
56
ExampleX U R1 R5 R6 R7
39 -CH2- S F -(CH2)3-O-CH3 ~I-0 --- H
40 -CH2- S F -(CH2)2-O-CH3 H
41 -CH2- S F -(CH2)2-0-(CH2)2- ~I-0 --- H
O-CH3
The potency of some of the described examples are indicated in the following
table:
Example PPARalpha PPARdelta
EC50 (pM) EC50 (pM)
9 0.06 0.02
14 0.07 0.004
23 0.82 0.65
24 1.35 0.27
28 1.02 0.06
33 1.10 1.80
39 0.36 0.20
Processes
The compounds of the general formula I according to the invention can be
obtained as
outlined to the reaction schemes below:
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
57
Process A
This process is used for synthesizing compounds of general formula A-7, where
X, U,
R1, R2, R3, R4, R5, R6, and R7 are as defined.
0
I I 1. MeOH, MS 4A
HR5 2. NaBH4 R6 N
R4 R1 A-2a R4 R1 R7U~HaI
Hi /X R3 ~-~ R2 CN A~
X ~-~ CN
HZN , DMF,
R3 R2 I Hal-R5 WC03, MeCN, ~ R5 MW 200 C
A-1 M A-3
A-2b
R6
R6 R4 R1
~N R4 R1 R7 / ~ NH
R7 ~~ NH2OH, NEt3 U /X
N/X - CN i H-OH
R
R2
R5 R3 R2 R5
A-5 A-6
R6
R4 R1
H p
1. phenylchloroformate, pyridine R7 ~ N
2. DBU, MeCN U N/X /-\ N,O
R5 R3 R2
A-7
A reductive amination with a primary amine of the general formula A-1 where X,
R1,
R2, R3 and R4 are as defined and an aldehyde of general formula A-2a where R5
is
as defined is performed in a solvent as methanol in the presence of molecular
sieves
4 Angstrom and by addition of a reducing agent as sodium borohydride to give a
secondary amine of the general formula A-3. Alternatively the primary amine of
the
general formula A-1 can be alkylated with an halide of general formula A-2b,
where R5
is as defined in a solvent as acetonitrile in presence of a base as potassium
carbonate
under microwave irradiation to give the secondary amine of the general formula
A-3.
The amine of general formula A-3 is reacted with an in two position
halogenated
thiazole, where U is S and R6 and R7 are as defined, or oxazole, where U is 0
and R6
and R7 are as defined in general formula A-4 under microwave irradiation at
elevated
temperature, e.g. 200 C, in a solvent as dimethylformamide in the presence of
a base
as N,N-diisopropylethylamine to give a compound of general formula A-5. The
compound of the general formula A-5 is reacted with hydroxylamine
hydrochloride in
the presence of a base as triethylamine in a solvent as tetrahydrofuran and
methanol
to obtain a compound of the general formula A-6. A compound of the general
formula
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
58
A-6 is converted to the product of general formula A-7 by reaction with
phenylchloroformate in the presence of a base as pyridine and treating this
intermediate with a base as 1,8-diazabicyclo[5.4.0]undec-7-ene in a solvent as
acetonitrile.
Examples 1-17 were obtained according to process A.
Other compounds can be obtained accordingly or by known processes.
Process B:
This process is used for synthesizing compounds of general formula B-8, where
X is -
CH2CH2- and U, R1, R2, R3, R4, R5, R6, and R7 are as defined.
O R4 R1 TOTU, NEt3, R6 N
HO R6 O R4 R1 BH3*THF
~_~ CN + ~N~NHZ DMF R7 U NH ~-~ CN
R7 U
R3 R2 B~ R3 R2
B-7 B"2
R6 R5-Hal R6
N R4 R1 B-5 R4 R1
R7~~N CN NaH, DMF R7 UN /~ CN NHZOH, NEt3
I --- I ~
H R3 R2 R5 R3 R2
B-4 B-6
R6 R1 R6
~ R4 NH 1. phenylchloroformate, pyridine R1
~ 2. DBU, MeCN R7 R4 N O
R7- N N-OH U ~
U I H I - N-O
R2
RS R3 R5 R3 R2
B-7 B-8
A carboxylic acid of general formula B-1 where R1, R2, R3 and R4 are as
defined is
condensed with a primary amine of general formula B-2 where R6 and R7 are as
defined with a coupling reagent as O-((Ethoxycarbonyl)cyanomethyleneamino)-
N,N,N',N'-tetramethyluronium tetrafluoroborat in a solvent as
dimethylformamide in the
presence of a base as triethylamine to give an amide of the general formula B-
3. The
amide of general formula B-3 is reduced with a reducing agent as borane
tetrahydrofuran complex in a polar aprotic solvent as tetrahydrofuran to
obtain a
secondary amine of general formula B-4. The secondary amine of general formula
B-4
is alkylated with a halide of general formula B-5, where R5 is as defined, in
the
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
59
presence of a base as sodium hydride in a solvent as dimethylformamide to give
a
tertiary amine of general formula B-6. The compound of the general formula B-6
is
reacted with hydroxylamine hydrochloride in the presence of a base as
triethylamine in
a solvent as tetrahydrofuran and methanol to obtain a compound of the general
formula B-7. A compound of the general formula B-7 is converted to the product
of
general formula B-8 by reaction with phenylchloroformate in the presence of a
base as
pyridine and treating this intermediate with a base as 1,8-
diazabicyclo[5.4.0]undec-7-
ene in a solvent as acetonitrile.
Examples 18-23 were obtained according to process B.
Other compounds can be obtained accordingly or by known processes.
Process C:
This process is used for synthesizing compounds of general formula C-7, where
X is -
CH2- and U, R1, R2, R3, R4, R5, R6, and R7 are as defined.
R6~! N
I~ ~>-Hal
R4 R1 R4 R1 /~
Hal DMF R5-N /\ R7 C~
CN + HZN-RS CN
C-2 DMF,
R3 R2 R3 R2 MW 200 C
C-1 C-3
R6
R6 R4 R1
R7-~~ R4 R1 R7 ~ NH
NHZOH, NEt3 U
UN CN i -OH
R3 R2
R5 R3 R2 R5
C-5 C-6
R6
R4 R1 H~O
N
N
1. phenylchloroformate, pyridine R7 / ~
2. DBU, MeCN UN N,0
R5 R3 R2
C-7
A benzylic halide of general formula C-1 where R1, R2, R3 and R4 are as
defined is
reacted with a primary amine of general formula C-2 where R5 is as defined in
a
solvent as dimethylformamide to give a secondary amine of the general formula
C-3.
The secondary amine of general formula C-3 is reacted with a in two position
halogenated thiazole, where U is S and R6 and R7 are as defined or oxazole,
where U
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
is 0 and R6 and R7 are as defined of general formula C-4 under microwave
irradiation
at elevated temperature, e.g. 200 C, in a solvent as dimethylformamide in the
presence of a base as N,N-diisopropyliethylamine to give a compound of general
formula C-5. The compound of the general formula C-5 is reacted with
hydroxylamine
5 hydrochloride in the presence of a base as triethylamine in a solvent as
tetrahydrofuran and methanol to obtain a compound of the general formula C-6.
A
compound of the general formula C-6 is converted to the product of general
formula C-
7 by reaction with phenylchloroformate in the presence of a base as pyridine
and
treating this intermediate with a base as 1,8-diazabicyclo[5.4.0]undec-7-ene
in a
10 solvent as acetonitrile.
Examples 24-37 were obtained according to process C.
Other compounds can be obtained accordingly or by known processes.
15 Process D:
This process is used for synthesizing compounds of general formula D-7, where
X is -
CH2- and U, R1, R2, R3, R4, R5, R6, and R7 are as defined.
R6
R4 R1
Hal R4 R1 R6 N R7 jj HaID~ R5
CN + 'I ~NHz UJI H CN
R7~U , NaH, DMF
R3 R2
R3 R2
D-3
D-1 D-2
R6
R6 R4 R1
R7-~X- R4 R1 R7 Z, N NH
CN NH2OH, NEt3 U-I~\
U~ ~N i -OH
R3 R2
R5 R3 R2 R5
D-5 D-6
R6
R4 R1 H O
1. phenylchloroformate, pyridine R7 / ~ N~
2. DBU, MeCN U N N_0
R5 R3 R2
D-7
20 A benzylic halide of general formula D-1 where R1, R2, R3 and R4 are as
defined is
reacted with a 2-amino-thiazole of general formula D-2, where U is S and R6
and R7
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
61
are with a 2-amino-oxazole, where U is 0 and R6 and R7 are as defined of
general
formula D-2 to give a secondary amine of the general formula D-3.
The secondary amine of general formula D-3 is alkylated with a halide of
general
formula D-4, where R5 is as defined, in the presence of a base as sodium
hydride in a
solvent as dimethylformamide to give a tertiary amine of general formula D-5.
The
compound of the general formula D-5 is reacted with hydroxylamine
hydrochloride in
the presence of a base as triethylamine in a solvent as tetrahydrofuran and
methanol
to obtain a compound of the general formula D-6. A compound of the general
formula
D-6 is converted to the product of general formula D-7 by reaction with
phenylchloroformate in the presence of a base as pyridine and treating this
intermediate with a base as 1,8-diazabicyclo[5.4.0]undec-7-ene in a solvent as
acetonitrile.
Examples 38-41 were obtained according to process D.
Other compounds can be obtained accordingly or by known processes.
Process E:
This process is used for synthesizing building blocks of general formula E-5,
which
correspond to general formula A-1 of process A, where X is -CH2CH2- and R1,
R2,
R3 and R4 are as defined.
R4 R1 PdO, NEt3, P(o-tolyl)3 HO R4 R1 HO R4 R1
DMF H2, Pd
Br CN O ~ *CN O CN
OH
R3 R2 R3 R2 R3 R2
O
E-1 E-2 E-3
O R4 R1
Diphenylphosphorylazide, 4 R4 R1 TFA, DCM HZN
NEt3, tert-butanol, reflux H ~~ CN
CN
R3 R2
R3 R2
E-1 E-5
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
62
A Bromobenzonitrile of general formula E-1 is cross coupled with acrylic acid
under
Heck reaction conditions, in the presence of a palladium source as
palladium(II)acetate, a ligand as Tri-o-tolyl-phosphine, a base as
triethylamine in a
solvent as acetonitrile to give a substituted acrylic acid of general formula
E-2. The
acrylic acid of general formula E-2 is hydrogenated in the presence of a
palladium
catalyst as palladium on charcoal (10%) in a solvent as methanol or a mixture
of
solvents as methanol and tetrahydrofuran under a hydrogen atmosphere to give a
carboxylic acid of general formula E-3. The carboxylic acid of general formula
E-3 is
rearranged to the BOC protected amine of general formula E-4 by treatment with
diphenylphosphorylazide in refluxing tert-butanol in the presence of a base as
triethylamine. The BOC protecting group of the amine of general formula E-4 is
removed by treatment with a base as trifluoroacetic acid in a solvent as
dichloromethane to give the primary amine of general formula E-5.
Other compounds can be obtained accordingly or by known processes.
Process F:
This process is used for synthesizing building blocks of general formula F-2,
which
correspond to general formula C-1 of process C, where Hal is bromine and R1,
R2, R3
and R4 are as defined and D-1 of process D, Hal is bromine and R1, R2, R3 and
R4
are as defined.
R4 R1 NBS, AIBN, CCI4, R4 R1
reflux Br
CN - CN
R3 R2 R3 R2
F-I F-2
A 4-methyl-benzonitrile of general formula F-1 is brominated by treatment with
N-
bromosuccinimide in the presence of a radical initiator as 2,2'-azobis(2-
methylpropionitrile) in a solvent as tetrachloromethane to give the
benzylbromide of
general formula F-2.
Other compounds can be obtained accordingly or by known processes.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
63
Process G:
This process is used for synthesizing building blocks of general formula G-2,
which
correspond to general formula A-4 of process A, where Hal is chlorine, U is S
and R6
and R7 are as defined and C-4 of process C, where Hal is chlorine, U is S and
R6
and R7 are as defined.
ONO, CUCI2,
R6 N MeCN R6 N
~CI
):U ~> -NH2 ):U
R7 R7 G-1 G-2
A 2-amino-thiazole of general formula G-1, where U is S and R6 and R7 are as
defined or a 2-amino-oxazole, where U is 0 and R6 and R7 are as defined is
reacted
with tert-butyl-nitrite and copper(II)chloride in a solvent as acetonitrile to
give a 2-
halogenated compound of general formula G-2.
Other compounds can be obtained accordingly or by known processes.
List of abbreviation:
Ac acetyl
AIBN 2,2'-azobis(2-methylpropionitrile)
Bn benzyl
BOC tert-butyl-oxy-carbonyl
iBu isobutyl
tBu tert-Butyl
BuLi n-butyllithium
Bz benzoyl
Cy cyclohexyl
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
DCI direct chemical ionization (MS)
DCM dichloromethane
DMAP N,N-dimethylaminopyridine
DMF N,N-dimethylformamide
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
64
DMSO dimethylsulfoxide
EE ethyl acetate
eq equivalents
ESI electrospray-lonisation (MS)
FG leaving group
GC gas chromatography
Hal halogen
HPLC high performance liquid chromatography
LC-MS liquid chromatography coupled with mass-spectroscopy
Me methyl
MeCN acetonitrile
MS mass-spectroscopy
MS 4A molecular sieves four angstrom
MsCI methansulfonylchloride
MW micro wave
NBS N-bromosuccinimide
NMR nuclear magnetic resonance
p para
Pd/C palladium on carbon
iPr isopropyl
nPr n-propyl
Rf retention factor (TLC)
tert tertiary
TFA trifluoroacetic acid
THF tetrahyd rofu ran
TLC thin layer chromatography
TOTU O-((Ethoxycarbonyl)cyanomethyleneamino)-N,N,N',N'-
tetramethyluronium tetrafluoroborat
Further compounds of the formula I can be prepared correspondingly or by known
processes.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
The experimental procedures for preparing the examples mentioned above are
described below:
Building block synthesis according to process E:
5
4-(2-Amino-ethyl)-2-methyl-benzonitrile
Pd , NEt3, P(o-tolyl)3 HO HO
DMF H2, Pd
Br ~ ~ \\ O ~ ~-\ \\ ~ O ~ \
- N ~ /OH \N
j ~O
O
Diphenylphosphorylazide, O \ H N
NEt3, tert-butanol, reflux N TFA, DCM 2
H N
N
10 (E)-3-(4-Cyano-3-methyl-phenyl)-acrylic acid
Pd , NEt3, P(o-tolyl)3 HO
DMF
Br CN O CN
- OH O
9.0 g 4-bromo-2-methylbenzonitrile, 2.76 g tri-o-tolylphosphine, 3.11 ml
acrylic acid
and 25.1 ml triethylamine are dissolved in 80 ml acetonitrile. The reaction
mixture is
15 degassed , then 2.0 g palladium (II)acetate were added and the mixture
stirred two
hours under microwave irradiation at 200 C. The cooled reaction mixture was
diluted
by addition of 50 ml ethylacetate. Thereby (E)-3-(4-Cyano-3-methyl-phenyl)-
acrylic
acid precipitated as a white solid. The precipitate was filtered off and dried
in vacuo to
obtain 2.5g (E)-3-(4-Cyano-3-methyl-phenyl)-acrylic acid. The filtrate was
washed with
20 1 N HCI, thereby (E)-3-(4-Cyano-3-methyl-phenyl)-acrylic acid precipitated
again as a
white solid. The precipitate was filtered off and dried in vacuo to obtain
2.Og (E)-3-(4-
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
66
Cyano-3-methyl-phenyl)-acrylic acid. The filtrate was reduced in vacuo to one
third of
its volume, 150 ml diethylether were added, thereby (E)-3-(4-Cyano-3-methyl-
phenyl)-
acrylic acid precipitated again as a white solid. The precipitate was filtered
off and
dried in vacuo to obtain 840 mg (E)-3-(4-Cyano-3-methyl-phenyl)-acrylic acid.
C11H9NO2 (187.20), MS(ESI): 188.1 (M+H+), Rf(ethyl acetate : methanol = 9:1) _
0.16.
3-(4-Cyano-3-methyl-phenyl)-propionic acid
HO
H2, Pd HO
O O
N \N
5.15 g (E)-3-(4-Cyano-3-methyl-phenyl)-acrylic acid were dissolved in a
mixture of 250
ml tetrahydrofuran and 125 ml methanol. 510 mg palladium on charcoal (10%)
were
added and the reaction mixture was stirred under a hydrogen atmosphere
overnight.
The catalyst was filtered off over a celite pad. The solvent was removed in
vacuo to
obtain 5.2 g 3-(4-Cyano-3-methyl-phenyl)-propionic acid as a white solid.
C11 H11 NO2 (189.22), MS(ESI): 190.2 (M+H+).
4-(2-Amino-ethyl)-2-methyl-benzon itrile
-~O
o
HO 4
Diphenylphosphorylazide N HZN
NEt3, tert-butanol, reflux H TFA, DCM
N N
xTFA
To a solution of 5.20 g 3-(4-Cyano-3-methyl-phenyl)-propionic acid and 4.57 ml
triethylamine in 100 ml tert-butanol 9.10 g diphenylphosphorylazide were given
and the
mixture heated under reflux overnight. The cooled reaction mixture was
evaporated in
vacuo. The resulting residue was dissolved in 150 ml ethyl acetate, washed
with 50 ml
citric acid/brine = 1:1 and 50 ml saturated NaHCO3 solution and then dried
over
MgSO4. The residue was dissolved in 50 ml dichloromethane and 20 ml
trifluoroacetic
acid were added. The reaction mixture was stirred at room temperature for two
hours.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
67
The solvent was removed in vacuo. The residue was coevaporated four times with
portions of 100 ml toluene. The resulting brown residue was taken up in 50 ml
acetonitrile and stirred at room temperature. The solid material was filtered
off and
dried in vacuo to obtain 2.45g 4-(2-Amino-ethyl)-2-methyl-benzonitrile as its
trifluoroacetate salt. The filtrate was evaporated in vacuo, the resulting
residue was
taken up in 100 ml diethylether and stirred at room temperature. The solid
material
was filtered off and dried in vacuo to obtain 1.17 g 4-(2-Amino-ethyl)-2-
methyl-
benzonitrile as its trifluoroacetate salt.
C10H12N2 xTFA (160.22 +xTFA), MS(ESI): 161.1 (M+H+).
Building block synthesis according to process F:
4-Bromomethyl-2-trifluoromethyl-benzonitrile
NBS, AIBN, CCI4, Br / ~
N reflux ~ N
F F
F F F F
To a refluxing mixture of 5.0 g 4-Methyl-2-(trifluoromethyl)benzonitrile in 50
ml
tetrachloromethane were added a mixture of 5.77 g N-bromosuccinimide and 1.77
g
2,2'-azobis(2-methylpropionitrile). The reaction mixture was heated under
reflux for
three hours. The reaction mixture was filtered throuph a pad of celite and the
solvent
was removed in vacuo to obtain 11.2 g crude 4-Bromomethyl-2-trifluoromethyl-
benzonitrile (impurified with the dibromo product) as a white solid. This
material was
used without further purification.
C9H5BrF3N (264.05), MS(ESI): 264.0, 266.0 (M+H+), Rf(n-heptane :ethyl acetate
=
4:1)=0.25.
Building block synthesis according to process G:
2-Chloro-6-trifluoromethyl-benzothiazole
oNO CuCl2, N
/ N~NH
2 ~ MeCN F ~ / I \CI
F ~ I S S
F F
F F
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
68
8.25 ml tert-butyl nitrite were added to a solution of 7.40 g copper (II)
chloride in 120 ml
acetonitrile. The reaction mixture was stirred ten minutes at room
temperature. Then a
solution of 10.0 g 2-Amino-6-(trifluoromethyl)benzonitrile were added. Then
100 ml 1 N
HCI were added to the cooled reaction mixture. The reaction mixture was
extracted
five times with portions of 50 ml ethyl acetate. The combined organic layers
were
washed with water and the dried over MgSO4. The solvent was removed in vacuo
to
obtain 9.79 g crude 2-Chloro-6-trifluoromethyl-benzothiazole as a red oil
which
solidifies upon standing. This material was used without further purification.
C8H3CIF3NS (237.63), MS(GC): 237.0 (M+H+), Rf(n-heptane :ethyl acetate = 1:1)
_
0.72.
The following examples were prepared according to process A:
Example 1
3-{4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-phenyl}-4H-[1,2,4]oxadiazol-5-
one
~ N O 1. MeOH, MS 4A
O TFA, DCM HzN N H 2. NaBH4
+
O -
a N
>CI
H O NH2OH, NEt3
N ~N~ , DMF, ~10 N
MW 200 C
N_ N NH 1. phenylchloroformate, pyridine N N O
2. DBU, MeCN N / \ ~
O H-OH O - N-O
4-(2-Amino-ethyl)-benzonitrile
A/ N / TFA, DCM HZN N
O\
0
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
69
1.90 g commercially available [2-(4-Cyano-phenyl)-ethyl]-carbamic acid tert-
butyl ester
were dissolved in 100 ml dichloromethane. 10 ml trifluoroacetic acid were
added and
the reaction mixture was stirred at room temperature for one hour. 250 ml
ethyl acetate
were added and the mixture was washed three times with saturated NaHCO3
solution.
The organic layer was dried over MgSO4 and then the solvent was removed in
vacuo
to obtain 700 mg 4-(2-Amino-ethyl)-benzonitrile as pale yellow solid.
C9H1ON2 (146.19), MS(ESI): 147.1 (M+H+).
4-(2-Butylamino-ethyl)-benzonitrile
O 1. MeOH, MS 4A
/\ N + H 2. NaBH4 H
HZN ;
_ _ \\
N
700 mg 4-(2-Amino-ethyl)-benzonitrile and 63 NI Butyraldehyde were dissolved
in 20
ml methanol. 1.0 g molecular sieves 4 Angstrom were added the mixture was
stirred at
room temperature for two hours. Then 270 mg sodium borohydride were added and
the mixture was stirred for an additional hour at room temperature. 100 ml
ethyl
acetate were added, and the reaction was quenched by addition of 1 ml water.
The
reaction mixture was filtered through a pad of celite and MgSO4. The filtrate
was
evaporated in vacuo to provide 750 mg crude 4-(2-Butylamino-ethyl)-
benzonitrile. This
material was used without further purification.
C13H18N2 (202.30), MS(ESI): 203.2 (M+H+).
4-[2-(Benzooxazol-2-yl-butyl-am ino)-ethyl]-benzonitrile
N
~-CI N
N \ I 0 N~ ~ ~ \\
H O N
N DMF,
MW 200 C
A solution of 750 mg 4-(2-Butylamino-ethyl)-benzonitrile, 854 mg 2-
chlorobenzooxazole and 0.95 ml N,N-diisopropylethylamine in 10 ml
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
dimethylformamide were stirred under microwave irradiation at 200 C for thirty
minutes. The cooled reaction mixture was diluted by the addition of 60 ml
ethyl
acetate, then washed three times with 40 ml brine. The organic layer was dried
over
MgSO4, then the solvent was removed in vacuo. The residue was purified by RP-
5 HPLC to obtain 290 mg 4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-
benzonitrile as pale
yellow amorphous solid.
C20H21N30 (319.41), MS(ESI): 320.2 (M+H+).
4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-N-hyd roxy-benzamid ine
N NHZOH, NEt3 N NH
6OOH
10 290 mg 4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-benzonitrile were
dissolved in a
mixture of 10 ml tetrahydrofuran and 20 ml methanol. 930 mg hydroxylamine
hydrochloride were added followed by the addition of 2.24 ml triethylamine.
The
reaction mixture was stirred at 65 C for two hours. The cooled reaction
mixture was
15 diluted by the addition of 100 ml ethyl acetate, then washed three times
with 40 ml
water. The organic layer was dried over MgSO4, then the solvent was removed in
vacuo to obtain 280 mg 4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-N-hydroxy-
benzamidine as a pale yellow oil.
C20H24N402 (352.44), MS(ESI): 353.2 (M+H+).
3-{4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-phenyl}-4H-[1,2,4]oxadiazol-5-
one
1. phenylchloroformate, pyridine H~O
N /\ NH 2. DBU, MeCN NN N
\
- N-OH O _O
H
280 mg 4-[2-(Benzooxazol-2-yl-butyl-amino)-ethyl]-N-hydroxy-benzamidine were
dissolved in 5 ml dichloromethane. 78 NI pyridine and 120 NI
phenylchloroformate were
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
71
added and the mixture stirred at room temperature for ten minutes. The mixture
was
diluted by the addition of 15 ml acetonitrile and 115 NI ml 1,8-
Diazabicyclo[5.4.0]undec-
7-ene were added. The mixture was stirred at room temperature for 10 minutes.
The
mixture was evaporated in vacuo and the resulting crude material was purified
by
reversed phase HPLC to obtain 105 mg 3-{4-[2-(Benzooxazol-2-yl-butyl-amino)-
ethyl]-
phenyl}-4H-[1,2,4]oxadiazol-5-one as an amorphous lyophilisate.
C21 H22N403 (378.43), MS(ESI): 379.2 (M+H+).
Example 2
3-{4-[2-(Benzothiazol-2-yl-butyl-amino)-ethyl]-phenyl}-4H-[1,2,4]oxadiazol-5-
one
N NO
N ~ ~ ~
/ ~ S - N-O
i
According to the method described in Example 1 3-{4-[2-(Benzothiazol-2-yl-
butyl-
amino)-ethyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one was obtained from 4-(2-
Butylamino-
ethyl)-benzonitrile and commercially available 2-chlorobenzothiazole.
C21 H22N402S (394.50), MS (ESI): 395.2 (M+H+).
Example 3
3-(4-{2-[Butyl-(6-methoxy-benzothiazol-2-yl)-amino]-ethyl}-phenyl)-4H-
[1,2,4]oxadiazol-
5-one
H O
N
N=( /_~ ~ J
S N' O
~O
According to the method described in Example 1 3-(4-{2-[Butyl-(6-methoxy-
benzothiazol-2-yl)-amino]-ethyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one was
obtained from
4-(2-Butylamino-ethyl)-benzonitrile and commercially available 2-Chloro-6-
methoxy-
benzothiazole.
C22H24N403S (424.53), MS (ESI): 425.2 (M+H+).
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
72
Example 4
3-(4-{2-[Butyl-(6-ch loro-benzoth iazol-2-yl)-am i no]-ethyl}-phenyl)-4 H-[ 1,
2,4]oxad iazol-5-
one
f q o
N
S N O
cl
According to the method described in Example 1 3-(4-{2-[Butyl-(6-chloro-
benzothiazol-
2-yl)-amino]-ethyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one was obtained from 4-(2-
Butylamino-ethyl)-benzonitrile and commercially available 2,6-
dichlorobenzothiazole.
C21 H21 CIN4O2S (428.94), MS (ESI): 429.2 (M+H+).
Example 5
3-(4-{2-[Butyl-(6-chloro-benzothiazol-2-yl)-amino]-ethyl}-2-methyl-phenyl)-4H-
[1,2,4]oxadiazol-5-one
1. MeOH, NEt3, MS 4A
HZN /~ H 2 NaBH4
+ -- ' H
xTFA / \ \\
N
~CI
az~~Is N
CI N
- Nz=( ~ ~ \\ NHZOH, NEt3
~N~ DMF, ~ S N
MW 200 C ~
CI
1. phenylchloroformate, pyridine
2. DBU, MeCN
N ~~ NH N N O
- N-OH N~ / \ \ --f
H -O
CI
CI
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
73
4-(2-Butylamino-ethyl)-2-methyl-benzonitrile
O 1. MeOH, NEt3, MS 4A
HZN /' N H 2. NaBH4
+ H ~ ~
* xTFA \N
138 mg 4-(2-Amino-ethyl)-2-methyl-benzonitrile trifluoro acetate, 210 pl
triethylamine
and 50 pl Butyraldehyde were dissolved in 5 ml methanol. 150 mg molecular
sieves 4
Angstrom were added and the mixture was stirred at room temperature overnight.
Then 21 mg sodium borohydride were added and the mixture was stirred for an
additional hour at room temperature. 50 ml ethyl acetate were added, and the
reaction
was quenched by addition of 0.5 ml water. The reaction mixture was filtered
through a
pad of celite and MgSO4. The filtrate was evaporated in vacuo to provide 230
mg
crude 4-(2-Butylamino-ethyl)-2-methyl-benzonitrile, impurified with salts.
This material
was used without further purification.
C14H2ON2 (216.33), MS(ESI): 217.2 (M+H+).
3-(4-{2-[Butyl-(6-chloro-benzothiazol-2-yl)-amino]-ethyl}-2-methyl-phenyl)-4H-
[1,2,4]oxadiazol-5-one
r, H 0
N=(N
/ \ IS N~O
q
According to the method described in Example 1 3-(4-{2-[Butyl-(6-chloro-
benzothiazol-
2-yl)-amino]-ethyl}-2-methyl-phenyl)-4H-[1,2,4]oxadiazol-5-one was obtained
from 4-
(2-Butylamino-ethyl)-2-methyl-benzonitrile and commercially available 2,6-
dichlorobenzothiazole.
C22H23CIN402S (442.97), MS (ESI): 443.1 (M+H+).
Example 6
3-(4-{2-[Butyl-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-ethyl}-2-methyl-
phenyl)-4H-
[1,2,4]oxadiazol-5-one
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
74
(/O
\ ~
N ~_\I
N-O
F F
According to the method described in Example 1 3-(4-{2-[Butyl-(6-
trifluoromethyl-
benzothiazol-2-yl)-amino]-ethyl}-2-methyl-phenyl)-4H-[1,2,4]oxadiazol-5-one
was
obtained from 4-(2-Butylamino-ethyl)-2-methyl-benzonitrile and 2-Chloro-6-
trifluoromethyl-benzothiazole.
C23H23F3N402S (476.52), MS (ESI): 477.2 (M+H+).
Example 7
3-(2-Methyl-4-{2-[[2-(tetrahyd ro-pyran-4-yl)-ethyl]-(6-trifl uoromethyl-
benzoth iazol-2-yl)-
amino]-ethyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one
O
~_\ \
N_~N
N I
S N,O
F
According to the method described in Example 1 and 5 3-(2-Methyl-4-{2-[[2-
(tetrahydro-pyran-4-yl)-ethyl]-(6-trifluoromethyl-benzothiazol-2-yl)-am ino]-
ethyl}-
phenyl)-4H-[1,2,4]oxadiazol-5-one was obtained from 4-(2-Amino-ethyl)-2-methyl-
benzonitrile trifluoro acetate, (tetrahydro-pyran-4-yl)-acetaldehyde and 2-
Chloro-6-
trifluoromethyl-benzothiazole.
C26H27F3N403S (532.59), MS (ESI): 533.1 (M+H+).
Example 8
3-(2-Methyl-4-{2-[(tetrahydro-pyran-3-ylmethyl)-(6-trifluoromethyl-
benzothiazol-2-yl)-
am ino]-ethyl}-phenyl)-4 H-[ 1, 2,4]oxad iazol-5-one
~(
N-/ ~ \
N I
1S N,O
F
F F
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
According to the method described in Example 1 and 5 3-(2-Methyl-4-{2-
[(tetrahydro-
pyran-3-ylmethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-am ino]-ethyl}-phenyl)-
4H-
[1,2,4]oxadiazol-5-one was obtained from 4-(2-Amino-ethyl)-2-methyl-
benzonitrile
trifluoro acetate, tetrahydropyranyl-3-carboxaldehyde and 2-Chloro-6-
trifluoromethyl-
5 benzothiazole.
C25H25F3N403S (518.56), MS (ESI): 519.1 (M+H+).
Example 9
3-(2-Methyl-4-{2-[(tetrahyd ro-pyran-4-ylmethyl)-(6-trifluoromethyl-benzoth
iazol-2-yl)-
10 amino]-ethyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one
rvo
N N~O
N~ -~ ~
S N-O
F
F F
According to the method described in Example 1 and 5 3-(2-Methyl-4-{2-
[(tetrahydro-
pyran-4-ylmethyl)-(6-trifluoromethyl-benzoth iazol-2-yl)-amino]-ethyl}-phenyl)-
4H-
[1,2,4]oxadiazol-5-one was obtained from 4-(2-Amino-ethyl)-2-methyl-
benzonitrile
15 trifluoro acetate, tetrahydropyranyl-4-carboxaldehyde and 2-Chloro-6-
trifluoromethyl-
benzothiazole.
C25H25F3N403S (518.56), MS (ESI): 519.1 (M+H+).
Example 10
20 3-(4-{2-[[2-(1-Acetyl-piperidin-4-yl)-ethyl]-(6-trifluoromethyl-
benzothiazol-2-yl)-amino]-
ethyl}-2-methyl-p henyl)-4H-[ 1, 2,4]oxad iazol-5-one
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
76
O'\ /O -~ 'YO
Ac20, pyridine,
TFA, DCM DMF
S
F/ S N / ~ \ S
F F F F F~
F
F F
-YO O
N N
NH=OH, NEt3
t. phenylchlorotortnate, pyridine
2. DBU, MeCN H~O
/ N NH / N ~
S N-OH S N-O
H
F F F F F
2-Methyl-4-{2-[(2-piperid in-4-yl-ethyl)-(6-trifluoromethyl-benzoth iazol-2-
yl)-amino]-
ethyl}-benzonitrile
oyot N
N
TFA, DCM
N~N
S IN S N
F F F
F F F
1.1 g 4-{2-[[2-(4-Cyano-3-methyl-phenyl)-ethyl]-(6-trifluoromethyl-
benzothiazol-2-yl)-
amino]-ethyl}-piperidine-l-carboxylic acid tert-butyl ester [prepared
according to the
method described in Example 1 and 5 from 4-(2-Amino-ethyl)-2-methyl-
benzonitrile
trifluoro acetate, N-boc-piperidinyl-4-acetaldehyde and 2-Chloro-6-
trifluoromethyl-
benzothiazole] were dissolved in 50 ml dichloromethane. 5 ml trifluoroacetic
acid were
added and the reaction mixture was stirred at room temperature for one hour.
150 ml
ethyl acetate were added and the mixture was washed three times with saturated
NaHCO3 solution. The organic layer was dried over MgSO4 and then the solvent
was
removed in vacuo. The residue was purified by RP-HPLC to obtain 325 mg 2-
Methyl-4-
{2-[(2-piperidin-4-yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
ethyl}-
benzonitrile.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
77
C25H27F3N4S (472.58), MS(ESI): 473.2 (M+H+).
4-{2-[[2-(1-Acetyl-piperid in-4-yl)-ethyl]-(6-trifluoromethyl-benzothiazol-2-
yl)-am ino]-
ethyl}-2-methyl-benzon itri le
H
N N
Ac20, pyridine,
DMF
---
N /_\ \ ~
S N s 'N
F F F F
F
160 mg 4-{2-[[2-(1-Acetyl-piperidin-4-yl)-ethyl]-(6-trifluoromethyl-
benzothiazol-2-yl)-
amino]-ethyl}-2-methyl-benzonitrile were dissolved in 2.5 ml
dimethylformamide. 5 ml
pyridine and 26 pl acetic acid anhydride were added. After being stirred at
room
temperature for thirty minutes, the reaction mixture was evaporated in vacuo
to obtain
140 mg crude 4-{2-[[2-(1-Acetyl-piperidin-4-yl)-ethyl]-(6-trifluoromethyl-
benzothiazol-2-
yl)-amino]-ethyl}-2-methyl-benzonitrile which was used in the next step
without further
purification.
C27H29F3N40S (514.62), MS(ESI): 515.2 (M+H+).
3-(4-{2-[[2-(1-Acetyl-piperidin-4-yl)-ethyl]-(6-trifluoromethyl-benzothiazol-2-
yl)-amino]-
ethyl}-2-methyl-phenyl)-4H-[1,2,4]oxadiazol-5-one
'Y o
N
N NO
S N-O
F
F F
According to the method described in Example 1 3-(4-{2-[[2-(1-Acetyl-piperidin-
4-yl)-
ethyl]-(6-trifluoromethyl-benzothiazol-2-yl)-am ino]-ethyl}-2-methyl-phenyl)-
4H-
[1,2,4]oxadiazol-5-one was obtained from 4-{2-[[2-(1-Acetyl-piperidin-4-yl)-
ethyl]-(6-
trifluoromethyl-benzothiazol-2-yl)-am ino]-ethyl}-2-methyl-benzonitrile.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
78
C28H30F3N503S (573.64), MS (ESI): 574.2 (M+H+).
Example 11
3-{4-[(Benzooxazol-2-yl-butyl-amino)-methyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one
0 1. MeOH, MS 4A
HZN /-\ N + H 2. NaBH4
~ HN
~-~
1I1J0 N
N~' N NH2OH, NEt3
~
DMF,
~ MW 200 C
r-r
N NH 1. hen Ichloroformate ridine ~ H 0
N P Y PY N
~
~ 2. DBU, MeCN N\ Y N
H-OH \ N~
4-Butylaminomethyl-benzonitrile
O 1. MeOH, MS 4A
H2N rN + H 2. NaBH4
~ HN
N
5.0 g 4-Aminomethyl-benzonitrile and 3.75 ml Butyraldehyde were dissolved in
40 ml
methanol. 3.0 g molecular sieves 4 Angstrom were added and the mixture was
stirred
at room temperature for two hours. Then 2.2 g sodium borohydride were added
and
the mixture was stirred for an additional hour at room temperature. 250 ml
ethyl
acetate were added, and the reaction was quenched by addition of 4 ml water.
The
reaction mixture was filtered through a pad of celite and MgSO4. The filtrate
was
evaporated in vacuo to provide 3.7 g crude 4-Butylaminomethyl-benzonitrile.
This
material was used without further purification.
C12H16N2 (188.27), MS(ESI): 189.2 (M+H+).
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
79
3-{4-[(Benzooxazol-2-yl-butyl-amino)-methyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one
N-r H 0
O N-0
According to the method described in Example 1 3-{4-[(Benzooxazol-2-yl-butyl-
amino)-methyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one was obtained from 4-
butylaminomethyl-benzonitrile and 2-chlorobenzoxazole.
C20H2ON403 (364.41), MS (ESI): 365.2 (M+H+).
Example 12
3-{4-[(Benzoth iazol-2-yl-butyl-am i no)-methyl]-phenyl}-4H-[ 1, 2,4]oxad
iazol-5-one
r-r H O
N~N
g N-O
-
According to the method described in Example 1 3-{4-[(Benzothiazol-2-yl-butyl-
amino)-methyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one was obtained from 4-
butylaminomethyl-benzonitrile and 2-chlorobenzothiazole.
C20H2ON402S (380.47), MS (ESI): 381.2 (M+H+).
Example 13
3-(4-{[B utyl-(6-ch loro-benzoth iazol-2-yl)-am i no]-methyl}-phenyl)-4 H-[ 1,
2,4]oxad iazol-5-
one
N-r H 0
g N,O
cl
According to the method described in Example 1 3-(4-{[Butyl-(6-chloro-
benzothiazol-2-
yl)-amino]-methyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one was obtained from 4-
butylaminomethyl-benzonitrile and 2,6-dichlorobenzothiazole.
C20H19CIN4O2S (414.92), MS (ESI): 415.1 (M+H+).
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
Example 14
3-(4-{2-[(3-Methoxy-propyl)-(6-trifluoromethyl-benzoth iazol-2-yl)-am ino]-
ethyl}-2-
methyl-phenyl)-4H-[1,2,4]oxadiazol-5-one
oll
Br
H2N ~-\ ~ N K2C03, MeCN
' xTFA / + 0 H /-\ \ N
N
F \ I \CI
S
F F N
N---~ ~ \ \\ NHZoH, NEt3
~N~ DMF, S - N
MW 200 C ~
F F
F
O1~
~ O
1. phenylchloroformate, pyridine
2. DBU, MeCN
N----(N NH N N O
S N-OH N~ /_\ \
H S N'
F
F F F
5 F F
4-[2-(3-Methoxy-propylamino)-ethyl]-2-methyl-benzonitrile
o1-1
H2N //N Br K2C03, MeCN
MW 120 C H
* xTFA + \
O~ ' xTFA N
A mixture of 500 mg 4-(2-Amino-ethyl)-2-methyl-benzonitrile trifluoro acetate
and 756
10 mg potassium carbonate were stirred in 10 ml acetonitrile at 80 C for
fifteen minutes.
Then 279 mg 1-bromo-3-methoxypropane, dissolved in 5 ml acetonitrile, were
added
dropwise at 80 C. The reaction mixture was stirred under micro wave
irradiation at
120 C for one hour. The cooled reaction mixture was filtered through a pad of
celite to
remove the salt. Then the solvent was removed in vacuo. The residue was
purified by
15 RP-HPLC to obtain 268 mg 4-[2-(3-Methoxy-propylamino)-ethyl]-2-methyl-
benzonitrile
as its trifluoroacetate salt.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
81
C14H2ON20 =xTFA (232.16+xTFA), MS(ESI): 233.2 (M+H+).
3-(4-{2-[(3-Methoxy-propyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
ethyl}-2-
methyl-phenyl)-4H-[1,2,4]oxadiazol-5-one
I
0
H O
NN ~ ~ ~
S _ NO
F
CJ F F
According to the method described in Example 1 3-(4-{2-[(3-Methoxy-propyl)-(6-
trifluoromethyl-benzothiazol-2-yl)-amino]-ethyl}-2-methyl-phenyl)-4H-
[1,2,4]oxad iazol-
5-one was obtained from 4-[2-(3-Methoxy-propylamino)-ethyl]-2-methyl-
benzonitrile
trifluoroacetate and 2-Chloro-6-trifluoromethyl-benzothiazole.
C23H23F3N403S (492.52), MS (ESI): 493.0 (M+H+).
Example 15
3-(4-{2-[[2-(2-Methoxy-ethoxy)-ethyl]-(6-trifluoromethyl-benzothiazol-2-yl)-
amino]-
ethyl}-2-methyl-phenyl)-4H-[1,2,4]oxadiazol-5-one
/o
oJ(
N N O
\
S N,O
F
F F
According to the method described in Example 1 and 14 3-(4-{2-[[2-(2-Methoxy-
ethoxy)-ethyl]-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-ethyl}-2-methyl-
phenyl)-4H-
[1,2,4]oxadiazol-5-one was obtained from 4-(2-Amino-ethyl)-2-methyl-
benzonitrile
trifluoro acetate, 1-bromo-2-(2-methoxyethoxy)ethane and 2-Chloro-6-
trifluoromethyl-
benzothiazole.
C24H25F3N404S (522.55), MS (ESI): 523.0 (M+H+).
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
82
Example 16
3-(4-{2-[(2-Benzyloxy-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
ethyl}-2-
methyl-phenyl)-4H-[1,2,4]oxadiazol-5-one
9
N
N iO
~ ~ ~ r
S - NO
F
F F
According to the method described in Example 1 and 14 3-(4-{2-[(2-Benzyloxy-
ethyl)-
(6-trifluoromethyl-benzothiazol-2-yl)-amino]-ethyl}-2-methyl-phenyl)-4H-
[1,2,4]oxadiazol-5-one was obtained from 4-(2-Amino-ethyl)-2-methyl-
benzonitrile
trifluoro acetate, benzyl 2-bromoethylether and 2-Chloro-6-trifluoromethyl-
benzothiazole.
C28H25F3N403S (554.60), MS (ESI): 555.0 (M+H+).
Example 17
3-(4-{2-[(2-Methoxy-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-ethyl}-
2-methyl-
phenyl)-4H-[1,2,4]oxadiazol-5-one
oll
~ N-/ O
N~ ~ I
S N0
F
FF
According to the method described in Example 1 and 14 3-(4-{2-[(2-Methoxy-
ethyl)-(6-
trifluoromethyl-benzothiazol-2-yl)-amino]-ethyl}-2-methyl-phenyl)-4H-
[1,2,4]oxadiazol-
5-one was obtained from 4-(2-Amino-ethyl)-2-methyl-benzonitrile trifluoro
acetate, 2-
bromoethyl methylether and 2-Chloro-6-trifluoromethyl-benzothiazole.
C22H21 F3N403S (478.50), MS (ESI): 479.0 (M+H+).
The following examples were prepared according to process B:
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
83
Example 18
3-[4-(2-{Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-amino}-ethyl)-phenyl]-4H-
[1,2,4]oxadiazol-5-one
-O
O
0 TOTU, NEt3, N O
HO I/ N DMF N BH3'THF
~~ CN t NHZ S H ~ ~ CN~
- S
-O -O ~
3-1 ; NHZOH, NEt3
Si ~\ CN , NaH, DMF S~N ~\ CN ~
H
O
-O
I / N NH ; N~O
~-- N 1 . phenylchloroformate, pyridine SN
g H-OH Z DBU, MeCN N-O
2-(4-Cya no-phenyl)-N-[4-(4-methoxy-phenyl)-th iazol-2-yl]-acetam ide
,o
~O
~ TOTU, NEt3, N O
HO / \ \ + / I N~NHz O-~ ~H
N S _ N
1.41 g 4-(4-Methoxyphenyl)-1,3-thiazol-2-amine was dissoveld in 2 ml
dimethylformamide. 3.0 ml N,N-Diisopropylethylamine, 1.0 g commercially
available (4-
Cyano-phenyl)-acetic acid and 2.25 g O-((Ethoxycarbonyl)cyanomethyleneamino)-
N,N,N',N'-tetramethyluronium tetrafluoroborat were added. The reaction mixture
was
stirred at room temperature overnight. Then 200 ml ethylacetate were added and
the
mixture was washed three times with portions of 50 mi saturated NaHCO3
solution and
then dried over MgSO4. The solvents were removed in vacuo and the residue
purified
by RP-HPLC to obtain 610 mg 2-(4-Cyano-phenyl)-N-[4-(4-methoxy-phenyl)-thiazol-
2-
yl]-acetamide as yellow solid.
C19H15N302S (349.41), MS (ESI): 350.1 (M+H+).
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
84
4-{2-[4-(4-Methoxy-phenyl)-th iazol-2-ylam ino]-ethyl}-benzonitrile
-O
'O
N O BH3*THF S ~
~ H ~ ~ -- ~
N si ~\ N
H
610 mg 2-(4-Cyano-phenyl)-N-[4-(4-methoxy-phenyl)-thiazol-2-yl]-acetamide were
suspended in 20 ml tetrahydrofuran. 2.1 ml of a one molar solution of borane
tetrahydrofuran complex were added at room temperature. The reaction mixture
was
stirred at room temperature for two hours and then at 50 C for two hours. The
cooled
reaction mixture was poured on 50 ml water and extracted five times with
portions of
50 ml ethyl acetate. The combined organic layers were dried over MgSO4. Then
the
solvents were removed in vacuo to obtain 600 mg 4-{2-[4-(4-Methoxy-phenyl)-
thiazol-
2-ylamino]-ethyl}-benzonitrile.
C19H17N3OS (335.43), MS (ESI): 336.2 (M+H+).
4-(2-{Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-am ino}-ethyl)-benzonitrile
~o ~o
N N
NaH, DMF 1
si ~ ~ \ N ---- SN ~ \ \ N
H
600 mg 4-{2-[4-(4-Methoxy-phenyl)-thiazol-2-ylamino]-ethyl}-benzonitrile were
dissolved in 30 ml dimethylformamide. 85.9 mg sodium hydride (24% in mineral
oil)
were added and the reaction mixture stirred at room temperature for thirty
minutes.
Then 245 NI 1-lodobutane were added and the reaction mixture stirred at room
temperature for two hours. Then 100 ml ethylacetate were added and the mixture
was
washed three times with portions of 50 ml water and then dried over MgSO4. The
solvents were removed in vacuo and the residue purified by RP-HPLC to obtain
279 mg 4-(2-{Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-amino}-ethyl)-
benzonitrile.
C23H25N30S (391.54), MS (ESI): 392.2 (M+H+).
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
3-[4-(2-{Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-am ino}-ethyl)-phenyl]-4H-
[1,2,4]oxadiazol-5-one
I~
0
SN ~\ C
N
According to the method described in Example 1 3-[4-(2-{Butyl-[4-(4-methoxy-
phenyl)-
5 thiazol-2-yl]-amino}-ethyl)-phenyl]-4H-[1,2,4]oxadiazol-5-one was obtained
from 4-(2-
{Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-amino}-ethyl)-benzonitrile.
C24H26N403S (450.56), MS (ESI): 451.2 (M+H+).
Example 19
10 3-[4-(2-{Butyl-[4-(4-chloro-phenyl)-thiazol-2-yl]-amino}-ethyl)-phenyl]-4H-
[1,2,4]oxadiazol-5-one
~ \ N 0
According to the method described in Example 1 and 18 3-[4-(2-{Butyl-[4-(4-
chloro-
phenyl)-thiazol-2-yl]-amino}-ethyl)-phenyl]-4H-[1,2,4]oxadiazol-5-one was
obtained
15 from (4-Cyano-phenyl)-acetic acid, 4-(4-Chloro-phenyl)-thiazol-2-ylamine
and 1-
lodobutane.
C23H23CIN4O2S (454.98), MS (ESI): 455.0 (M+H+).
Example 20
20 3-(4-{2-[[4-(4-Chloro-phenyl)-thiazol-2-yl]-(3-methoxy-propyl)-amino]-
ethyl}-phenyl)-4H-
[1,2,4]oxadiazol-5-one
H ci ~
I~
0
~SN
N,O
-0
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
86
According to the method described in Example 1 and 18 3-(4-{2-[[4-(4-Chloro-
phenyl)-
thiazol-2-yl]-(3-methoxy-propyl)-amino]-ethyl}-phenyl)-4H-[1,2,4]oxadiazol-5-
one was
obtained from (4-Cyano-phenyl)-acetic acid, 4-(4-Chloro-phenyl)-thiazol-2-
ylamine and
1 -bromo-3-methoxypropane.
C23H23CIN403S (470.98), MS (ESI): 471.0 (M+H+).
Example 21
3-[4-(2-{[4-(4-Chloro-phenyl)-thiazol-2-yl]-[2-(2-methoxy-ethoxy)-ethyl]-
amino}-ethyl)-
phenyl]-4H-[1,2,4]oxadiazol-5-one
ci
H 0
/SN-I
\ ~ J N-O
~/\(
'
According to the method described in Example 1 and 18 3-[4-(2-{[4-(4-Chloro-
phenyl)-
thiazol-2-yl]-[2-(2-methoxy-ethoxy)-ethyl]-amino}-ethyl)-phenyl]-4H-
[1,2,4]oxadiazol-5-
one was obtained from (4-Cyano-phenyl)-acetic acid, 4-(4-Chloro-phenyl)-
thiazol-2-
ylamine and 1-bromo-2-(methoxyethoxy)ethane.
C24H25CIN404S (501.01), MS (ESI): 501.0 (M+H+).
Example 22
3-[4-(2-{(2-Benzyloxy-ethyl)-[4-(4-chloro-phenyl)-th iazol-2-yl]-amino}-ethyl)-
phenyl]-4H-
[1,2,4]oxadiazol-5-one
H
/ \\ \ N,
-O
N
According to the method described in Example 1 and 18 3-[4-(2-{(2-Benzyloxy-
ethyl)-
[4-(4-chloro-phenyl)-thiazol-2-yl]-amino}-ethyl)-phenyl]-4H-[1,2,4]oxadiazol-5-
one was
obtained from (4-Cyano-phenyl)-acetic acid, 4-(4-Chloro-phenyl)-thiazol-2-
ylamine and
benzyl 2-bromoethylether.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
87
C28H25CIN403S (533.05), MS (ESI): 533.1 (M+H+).
Example 23
3-(4-{2-[[4-(4-Ch loro-phenyl)-th iazol-2-yl]-(2-methoxy-ethyl)-amino]-ethyl}-
phenyl)-4H-
[1,2,4]oxadiazol-5-one
ci
I
~ \ N 0
S~N Xl\ -0
N
0
According to the method described in Example 1 and 18 3-(4-{2-[[4-(4-Chloro-
phenyl)-
thiazol-2-yl]-(2-methoxy-ethyl)-amino]-ethyl}-phenyl)-4H-[1,2,4]oxadiazol-5-
one was
obtained from (4-Cyano-phenyl)-acetic acid, 4-(4-Chloro-phenyl)-thiazol-2-
ylamine and
2-bromoethylmethylether.
C22H21CIN4O3S (456.95), MS (ESI): 457.0 (M+H+).
The following examples were prepared according to process C:
Example 24
3-(4-{[Butyl-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-2-fluoro-
phenyl)-4H-
[1,2,4]oxadiazol-5-one
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
88
r-I F >CI
Br
DMF HN F F
+ ~~NHZ CN
DMF,
CN F MW 200 C
F
F
F F
F NH
F \ I,., \
'-I\
S'" CN NH2OH, NEt3 S N - H-OH
N ~_~ F
F
F
F
F
~ H O
1. phenylchloroformate, pyridine ~
2. DBU, MeCN N
N-
O
F
4-Butylaminomethyl-2-fluoro-benzonitrile
Br
DMF HN
\\ + ~~~NHz -y \\
N N
F F
4.64 mi n-butylamine was dissolved in 30 ml dimethylformamide. 667 mg
commercially
available 4-cyano-3-fluorobenzylbromide, dissolved in 10 ml dimethylformamide
was
added dropwise. The reaction mixture was stirred at room temperature for
thirty
minutes. The solvent was removed in vacuo and the residue prurified by
chromatography on silica gel with the eluent n-heptane:ethyl acetate = 1:4 =>
ethyl
acetate : methanol = 4:1 to obtain 360 mg 4-Butylaminomethyl-2-fluoro-
benzonitrile.
C12H15FN2 (206.27), MS (ESI): 207.2 (M+H+), Rf(ethyl acetate : methanol = 9:1)
_
0.29.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
89
3-(4-{[Butyl-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-2-fluoro-
phenyl)-4H-
[1,2,4]oxadiazol-5-one
F
F
F X IN N O
~NI- \
N10
F
According to the method described in Example 1 3-(4-{[Butyl-(6-trifluoromethyl-
benzothiazol-2-yl)-amino]-methyl}-2-fluoro-phenyl)-4H-[1,2,4]oxadiazol-5-one
was
obtained from 4-Butylaminomethyl-2-fluoro-benzonitrile and 2-Chloro-6-
trifluoromethyl-
benzothiazole.
C21 H18F4N402S (466.46), MS (ESI): 467.0 (M+H+).
Example 25
3-(4-{[Butyl-(6-ch loro-benzothiazol-2-yl)-amino]-methyl}-2-fluoro-phenyl)-4H-
[1,2,4]oxadiazol-5-one
CI IN N H O
SN /_\ \ I
O
N-
F
According to the method described in Example 1 3-(4-{[Butyl-(6-chloro-
benzothiazol-2-
yl)-amino]-methyl}-2-fluoro-phenyl)-4H-[1,2,4]oxadiazol-5-one was obtained
from 4-
Butylaminomethyl-2-fluoro-benzonitrile and 2,6-dichloro-benzothiazole.
C20H18CIFN4O2S (432.91), MS (ESI): 433.0 (M+H+).
Example 26
3-(2-Fluoro-4-{[(2-pyrrolidin-l-yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-
yl)-amino]-
methyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
F
F
F I\ IN N~O
SN /\ -O
F
O
F~
F OH
According to the method described in Example 1 3-(2-Fluoro-4-{[(2-pyrrolidin-1-
yl-
ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-phenyl)-4H-
[1,2,4]oxad iazol-
5-one was obtained from commercially available 4-cyano-3-fluorobenzylbromide,
N-(2-
5 aminoethyl)pyrrolidine and 2-Chloro-6-trifluoromethyl-benzothiazole. After
RP-HPLC
the compound was obtained as its trifluoroacetate salt.
C23H21 F4N502S * C2HF302 (507.51+114.02), MS (ESI): 508.2 (M+H+).
Example 27
10 3-(4-{[(2-Dimethylamino-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
methyl}-2-
fluoro-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
F
F I\ N NO
SA\N ~-~ N-O
F
O
N- F
F _JA OH
F
According to the method described in Example 1 3-(4-{[(2-Dimethylamino-ethyl)-
(6-
trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-2-fluoro-phenyl)-4H-
[1,2,4]oxadiazol-
15 5-one was obtained from commercially available 4-cyano-3-
fluorobenzylbromide, N,N-
dimethylethylenediamine and 2-Chloro-6-trifluoromethyl-benzothiazole. After RP-
HPLC
the compound was obtained as its trifluoroacetate salt.
C21H19F4N502S* C2HF302 (481.48+114.02), MS (ESI): 482.2 (M+H+).
20 Example 28
3-(2-Fluoro-4-{[(2-methoxy-ethyl)-(6-trifluoromethyl-benzoth iazol-2-yl)-
amino]-methyl}-
phenyl)-4H-[1,2,4]oxadiazol-5-one
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
91
F
F
F \ X IN NO
SN N,O
F
0
According to the method described in Example 1 3-(2-Fluoro-4-{[(2-methoxy-
ethyl)-(6-
trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-phenyl)-4H-[1,2,4]oxad iazol-
5-one
was obtained from commercially available 4-cyano-3-fluorobenzylbromide, 2-
methoxyethylamine and 2-Chloro-6-trifluoromethyl-benzothiazole.
C20H16F4N403S (468.43), MS (ESI): 469.1 (M+H+).
Example 29
3-(2-Fluoro-4-{[(2-piperidin-1-yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-
amino]-
methyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
F
F
F I\ IN N~O
S/1\N /\ -O
F
O
F OH
a F
According to the method described in Example 1 3-(2-Fluoro-4-{[(2-piperidin-1-
yl-
ethyl)-(6-trifl uoromethyl-benzoth iazol-2-yl)-am i no]-methyl}-phenyl)-4 H-[
1, 2,4]oxad iazol-
5-one was obtained from commercially available 4-cyano-3-fluorobenzylbromide,
1-(2-
aminoethyl)piperidine and 2-Chloro-6-trifluoromethyl-benzothiazole. After RP-
HPLC
the compound was obtained as its trifluoroacetate salt.
C24H23F4N502S* C2HF302 (521.54+114.02), MS (ESI): 522.2 (M+H+).
Example 30
3-(2-Fluoro-4-{[(2-morpholin-4-yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-
amino]-
methyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
92
F
F
F IN N~O
S~N Q N,O
F
O
F~
F OH
0 F
According to the method described in Example 1 3-(2-Fluoro-4-{[(2-morpholin-4-
yl-
ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-phenyl)-4H-[
1,2,4]oxad iazol-
5-one was obtained from commercially available 4-cyano-3-fluorobenzylbromide,
N-(2-
aminoethyl)morpholine and 2-Chloro-6-trifluoromethyl-benzothiazole. After RP-
HPLC
the compound was obtained as its trifluoroacetate salt.
C23H21F4N503S* C2HF302 (523.51+114.02), MS (ESI): 524.2 (M+H+).
Example 31
3-(2-Fluoro-4-{[[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-(6-trifluoromethyl-
benzothiazol-2-yl)-
amino]-methyl}-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
F
F
F I\ /I IN NO
N-O
F
O
N F
F~OH
F
According to the method described in Example 1 3-(2-Fluoro-4-{[[2-(1-methyl-
pyrrolid in-2-yl)-ethyl]-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-
phenyl)-4H-
[1,2,4]oxadiazol-5-one was obtained from commercially available 4-cyano-3-
fluorobenzylbromide, 2-(2-aminoethyl)-1-methylpyrrolidine and 2-Chloro-6-
trifluoromethyl-benzothiazole. After RP-HPLC the compound was obtained as its
trifluoroacetate salt.
C24H23F4N502S* C2HF302 (521.54+114.02), MS (ESI): 522.2 (M+H+).
Example 32
3-(4-{[(2-Pyrrolidin-1 -yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
methyl}-2-
trifluoromethyl-phenyl)-4H-[1,2,4]oxad iazol-5-one
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
93
F
F
F ~. / I NO
S N /-\ N~0
F F
F O
N F~
F OH
F
According to the method described in Example 1 3-(4-{[(2-Pyrrolidin-1-yl-
ethyl)-(6-
trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-2-trifluoromethyl-phenyl)-4H-
[1,2,4]oxadiazol-5-one was obtained from 4-Bromomethyl-2-trifluoromethyl-
benzonitrile, N-(2-aminoethyl)pyrrolidine and 2-Chloro-6-trifluoromethyl-
benzothiazole.
After RP-HPLC the compound was obtained as its trifluoroacetate salt.
C24H21 F6N502S * C2HF302 (557.52+114.02), MS (ESI): 558.0 (M+H+).
Example 33
3-(4-{[(2-Dimethylamino-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
methyl}-2-
trifluoromethyl-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
F
F
F \ / ~ N~O
S
N N~0
F
F F O
N- F\ ~
F" O
F
According to the method described in Example 1 3-(4-{[(2-Dimethylamino-ethyl)-
(6-
trifluoromethyl-benzothiazol-2-yi)-am ino]-methyl}-2-trifluoromethyl-phenyl)-4
H-
[1,2,4]oxadiazol-5-one was obtained from 4-Bromomethyl-2-trifluoromethyl-
benzonitrile, N,N-dimethylethylenediamine and 2-Chloro- 6-trifluoromethyl-
benzothiazole. After RP-HPLC the compound was obtained as its trifluoroacetate
salt.
C22H19F6N502S* C2HF302 (531.48+114.02), MS (ESI): 532.1 (M+H+).
Example 34
3-(4-{[(2-Methoxy-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-
2-
trifl uoromethyl-phenyl)-4 H-[ 1, 2,4]oxad iazol-5-one
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
94
F
F
F I\ /I IN NO
N r~O
F F F
O
According to the method described in Example 1 3-(4-{[(2-Methoxy-ethyl)-(6-
trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-2-trifluoromethyl-phenyl)-4H-
[1,2,4]oxadiazol-5-one was obtained from 4-Bromomethyl-2-trifluoromethyl-
benzonitrile, 2-methoxyethylamine and 2-Chloro-6-trifluoromethyl-
benzothiazole.
C21 H16F6N403S (518.44), MS (ESI): 519.2 (M+H+).
Example 35
3-(4-{[(2-Piperidin-1-yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
methyl}-2-
trifluoromethyl-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
F
F
F ~ ~ N N~O O
S/~1\N /-\ N-O F~OH
F F
F F
0 N
According to the method described in Example 1 3-(4-{[(2-Piperidin-1-yl-ethyl)-
(6-
trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-2-trifluoromethyl-phenyl)-4H-
[1,2,4]oxadiazol-5-one was obtained from 4-Bromomethyl-2-trifluoromethyl-
benzonitrile, 1-(2-aminoethyl)piperidine and 2-Chloro-6-trifluoromethyl-
benzothiazole.
After RP-HPLC the compound was obtained as its trifluoroacetate salt.
C25H23F6N502S * C2HF302 (571.55+114.02), MS (ESI): 572.2 (M+H+).
Example 36
3-(4-{[(2-Morpholin-4-yl-ethyl)-(6-trifluoromethyl-benzothiazol-2-yl)-amino]-
methyl}-2-
trifluoromethyl-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
F
F
F I\ N N~O O jl-
S/1\N /- r-O F_ OH
~ F
F F 0 According to the method described in Example 1 3-(4-{[(2-Morpholin-4-yl-
ethyl)-(6-
trifluoromethyl-benzothiazol-2-yl)-amino]-methyl}-2-trifluoromethyl-phenyi)-4H-
[1,2,4]oxadiazol-5-one was obtained from 4-Bromomethyl-2-trifluoromethyl-
5 benzonitrile, N-(2-aminoethyl)morpholine and 2-Chloro-6-trifluoromethyl-
benzothiazole.
After RP-HPLC the compound was obtained as its trifluoroacetate salt.
C24H21 F6N503S * C2HF302 (573.52+114.02), MS (ESI): 574.2 (M+H+).
Example 37
10 3-(4-{[[2-(1-Methyl-pyrrolidin-2-yl)-ethyl]-(6-trifluoromethyl-benzothiazol-
2-yl)-amino]-
methyl}-2-trifluoromethyl-phenyl)-4H-[1,2,4]oxadiazol-5-one trifluoroacetate
F
F
F IN N O
S ~ ~ \
N - N~O FOH
F IF
F F
N
According to the method described in Example 1 3-(4-{[[2-(1-Methyl-pyrrolidin-
2-yl)-
ethyl]-(6-trifluoromethyl-benzoth iazol-2-yl)-amino]-methyl}-2-trifluoromethyl-
phenyl)-4H-
15 [1,2,4]oxadiazol-5-one was obtained from 4-Bromomethyl-2-trifluoromethyl-
benzonitrile, 2-(2-aminoethyl)-1-methylpyrrolidine and 2-Chloro-6-
trifluoromethyl-
benzothiazole. After RP-HPLC the compound was obtained as its trifluoroacetate
salt.
C25H23F6N502S * C2HF302 (571.55+114.02), MS (ESI): 572.2 (M+H+).
20 The following examples were prepared according to process D:
Example 38
3-[4-({Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-amino}-methyl)-phenyl]-4H-
[1,2,4]oxadiazol-5-one
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
96
~
0
Br Mw DMF,
ioo c
~=J "\ + N
N I S>--NHz i NaH, DMF
~ SN /-\ \N
H
O /
N
NHZOH, NEt3 N NH
S/\
N ~
N-OH
H
-0
1. phenylchloroformate, pyridine
2. DBU, MeCN
HO
N N-0
4-{[4-(4-Methoxy-phenyl)-thiazol-2-ylamino]-methyl}-benzonitrile
~
0
sr Mw ioo c
+ N
N I S~NH2 N
S / \ \~
N N
H
5.0 g 4-(4-Methoxyphenyl)-1,3-thiazol-2-amine, 4.29 g 4-bromomethyl-
benzonitrile and
6.0 ml N,N.Diisopropylethylamine were suspended in 20 ml dimethylformamide.
The
reaction mixture was stirred under microwave irradiation at 100 C for thirty
minutes.
The cooled reaction mixture was diluted by the addition of 100 ml ethylacetate
and
washed 50 ml saturated NaHCO3 solution and the dried over MgSO4. The solvent
was
removed in vacuo and the resulting residue was purified by chromatography on
silica
gel with the eluent petroleum ether: ethyl acetate = 3 : 2 to obtain 2.41 g 4-
{[4-(4-
Methoxy-phenyl)-thiazol-2-ylamino]-methyl}-benzonitrile.
C18H15N3OS (321.40), MS (ESI): 322.1 (M+H+), Rf(n-heptane : ethyl acetate =
1:1) _
0.29.
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
97
4-({Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-am ino}-methyl)-benzon itrile
o
N I , NaH, DMF IN
S \\ N /_\ \\
N N N
H
1.0 g 4-{[4-(4-Methoxy-phenyl)-thiazol-2-ylamino]-methyl}-benzonitrile was
dissolved in
150 ml dimethylformamide. 150 mg sodium hydride (24% in mineral oil) were
added
and the reaction mixture stirred at room temperature for thirty minutes. Then
0.43 ml 1-
lodobutane were added and the reaction mixture stirred at room temperature for
two
hours. Then 100 ml ethylacetate were added and the mixture was washed three
times
with portions of 50 ml water and then dried over MgSO4. The solvents were
removed
in vacuo to obtain 1.2 g 4-({Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-amino}-
methyl)-
benzonitrile.
C22H23N30S (377.51), MS (ESI): 378.2 (M+H+).
3-[4-({Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-amino}-methyl)-phenyl]-4H-
[1,2,4]oxadiazol-5-one
-0
\
N HO
N~O
According to the method described in Example 1 3-[4-({Butyl-[4-(4-methoxy-
phenyl)-
thiazol-2-yl]-amino}-methyl)-phenyl]-4H-[1,2,4]oxadiazol-5-one was obtained
from 4-
({Butyl-[4-(4-methoxy-phenyl)-thiazol-2-yl]-amino}-methyl)-benzonitrile.
C23H24N403S (436.54), MS (ESI): 437.4 (M+H+).
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
98
Example 39
3-(4-{[[4-(4-Chloro-phenyl)-thiazol-2-yl]-(3-methoxy-propyl)-amino]-methyl}-2-
fluoro-
phenyl)-4H-[1,2,4]oxad iazol-5-one
ci
F
N HO
S~ / \ \
N - N-0
0
1
According to the method described in Example 1 and 38 3-(4-{[[4-(4-Chloro-
phenyl)-
thiazol-2-yl]-(3-methoxy-propyl)-amino]-methyl}-2-fluoro-phenyl)-4H-[
1,2,4]oxad iazol-5-
one was obtained from 2-amino-4-(4-chlorophenyl)thiazole, 4-cyano-3-
fluorobenzylbromide and 1-bromo-3-methoxypropane .
C22H2OCIFN4O3S (474.95), MS (ESI): 475.0 (M+H+).
Example 40
3-(4-{[[4-(4-Ch loro-phenyl)-thiazol-2-yl]-(2-methoxy-ethyl)-amino]-methyl}-2-
fluoro-
phenyl)-4H-[1,2,4]oxadiazol-5-one
ci
\
F
N H-fO
S~ / \ \
N N,O
0
1
According to the method described in Example 1 and 38 3-(4-{[[4-(4-Chloro-
phenyl)-
thiazol-2-yl]-(2-methoxy-ethyl)-amino]-methyl}-2-fluoro-phenyl)-4H-
[1,2,4]oxadiazol-5-
one was obtained from 2-amino-4-(4-chlorophenyl)thiazole, 4-cyano-3-
fluorobenzylbromide and 2-bromoethylmethylether.
C21 H18CIFN4O3S (460.92), MS (ESI): 461.0 (M+H+).
CA 02624100 2008-03-27
WO 2007/039176 PCT/EP2006/009302
99
Example 41
3-[4-({[4-(4-Chloro-phenyl)-th iazol-2-yl]-[2-(2-methoxy-ethoxy)-ethyl]-amino}-
methyl)-2-
fluoro-phenyl]-4H-[1,2,4]oxadiazol-5-one
ci
F
I NC
S N N-O
~
~O
According to the method described in Example 1 and 38 3-[4-({[4-(4-Chloro-
phenyl)-
thiazol-2-yl]-[2-(2-methoxy-ethoxy)-ethyl]-amino}-methyl)-2-fluoro-phenyl]-4H-
[1,2,4]oxadiazol-5-one was obtained from 2-amino-4-(4-chlorophenyl)thiazole, 4-
cyano-3-fluorobenzylbromide and 1-bromo-2-(2-methoxyethoxy)ethane.
C23H22CIFN404S (504.97), MS (ESI): 505.1 (M+H+).
